WO2022260719A1 - Novel rna composition and production method for use in ips cell generation - Google Patents
Novel rna composition and production method for use in ips cell generation Download PDFInfo
- Publication number
- WO2022260719A1 WO2022260719A1 PCT/US2022/013372 US2022013372W WO2022260719A1 WO 2022260719 A1 WO2022260719 A1 WO 2022260719A1 US 2022013372 W US2022013372 W US 2022013372W WO 2022260719 A1 WO2022260719 A1 WO 2022260719A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rna
- seq
- composition
- mir
- rdrp
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 238000004519 manufacturing process Methods 0.000 title abstract description 22
- 108060004795 Methyltransferase Proteins 0.000 claims abstract description 95
- 108091030789 miR-302 stem-loop Proteins 0.000 claims abstract description 93
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 80
- 210000004027 cell Anatomy 0.000 claims abstract description 75
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 36
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000002243 precursor Substances 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 230000008672 reprogramming Effects 0.000 claims description 21
- 238000000338 in vitro Methods 0.000 claims description 16
- 230000003834 intracellular effect Effects 0.000 claims description 16
- 230000035897 transcription Effects 0.000 claims description 16
- 238000013518 transcription Methods 0.000 claims description 16
- 210000000130 stem cell Anatomy 0.000 claims description 15
- 238000001890 transfection Methods 0.000 claims description 15
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 12
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 239000002105 nanoparticle Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 241001493065 dsRNA viruses Species 0.000 claims description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 6
- 230000001976 improved effect Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229940124447 delivery agent Drugs 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000004520 electroporation Methods 0.000 claims description 5
- 230000001268 conjugating effect Effects 0.000 claims description 4
- 210000003981 ectoderm Anatomy 0.000 claims description 4
- 210000001900 endoderm Anatomy 0.000 claims description 4
- 210000001654 germ layer Anatomy 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 210000003716 mesoderm Anatomy 0.000 claims description 4
- ZGPHAZHLWWSPMV-UHFFFAOYSA-N 1-amino-3,4,5-trihydroxypentan-2-one Chemical class NCC(=O)C(O)C(O)CO ZGPHAZHLWWSPMV-UHFFFAOYSA-N 0.000 claims description 3
- 239000007993 MOPS buffer Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108020000999 Viral RNA Proteins 0.000 claims description 2
- 229960003237 betaine Drugs 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract description 26
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 210000004504 adult stem cell Anatomy 0.000 abstract description 7
- 230000009261 transgenic effect Effects 0.000 abstract description 3
- 229920002477 rna polymer Polymers 0.000 description 114
- 150000007523 nucleic acids Chemical class 0.000 description 48
- 102000039446 nucleic acids Human genes 0.000 description 47
- 108020004707 nucleic acids Proteins 0.000 description 47
- 108020004414 DNA Proteins 0.000 description 41
- 102000053602 DNA Human genes 0.000 description 38
- 108700011259 MicroRNAs Proteins 0.000 description 29
- 230000000692 anti-sense effect Effects 0.000 description 29
- 125000003729 nucleotide group Chemical group 0.000 description 25
- 239000002773 nucleotide Substances 0.000 description 24
- 239000004055 small Interfering RNA Substances 0.000 description 23
- 239000002679 microRNA Substances 0.000 description 21
- 108020004635 Complementary DNA Proteins 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 238000003752 polymerase chain reaction Methods 0.000 description 17
- 108091027967 Small hairpin RNA Proteins 0.000 description 15
- 238000010804 cDNA synthesis Methods 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 15
- 210000001082 somatic cell Anatomy 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 14
- 238000010839 reverse transcription Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 230000003321 amplification Effects 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 108020004459 Small interfering RNA Proteins 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000001671 embryonic stem cell Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000012761 co-transfection Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 108020005544 Antisense RNA Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 5
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 5
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108091027963 non-coding RNA Proteins 0.000 description 5
- 102000042567 non-coding RNA Human genes 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 210000001236 prokaryotic cell Anatomy 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 206010043276 Teratoma Diseases 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 229940022399 cancer vaccine Drugs 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000005030 transcription termination Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 230000035131 DNA demethylation Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108020005093 RNA Precursors Proteins 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000009191 jumping Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- 229960004854 viral vaccine Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- CBUWTGCATVNMJE-UHFFFAOYSA-N 6,6-dimethylheptanal Chemical compound CC(C)(C)CCCCC=O CBUWTGCATVNMJE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 238000012270 DNA recombination Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 229930185560 Pseudouridine Natural products 0.000 description 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 101150086694 SLC22A3 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000037440 gene silencing effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940090343 human menopausal gonadotrophin Drugs 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 108091062637 miR-367 stem-loop Proteins 0.000 description 2
- 108091057188 miR-369 stem-loop Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 150000002972 pentoses Chemical class 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000016596 traversing start control point of mitotic cell cycle Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 241000014654 Adna Species 0.000 description 1
- 239000012116 Alexa Fluor 680 Substances 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 102000002494 Endoribonucleases Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001128634 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100032194 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Human genes 0.000 description 1
- 101000892448 Neisseria gonorrhoeae Type II restriction enzyme NgoMIV Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000010357 RNA editing Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241001408665 Timandra griseata Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 230000008316 intracellular mechanism Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108091084454 miR-302a stem-loop Proteins 0.000 description 1
- 108091050195 miR-302b stem-loop Proteins 0.000 description 1
- 108091056763 miR-302c stem-loop Proteins 0.000 description 1
- 108091053185 miR-302d stem-loop Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001805 pentosyl group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- -1 rRNA Proteins 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000012144 step-by-step procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- TITLE Novel RNA Composition and Production Method for Use in iPS Cell
- This invention generally relates to a novel RNA composition and its production method useful for generating and expanding induced pluripotent stem cells (iPS cells; iPSC) as well as adult stem cells (ASC).
- the RNA composition so defined can be used for producing not only non-transgenic but also tumor-free iPS cells.
- the defined RNA composition contans at least two types of different RNA constructs; one is “miR-302 precursor RNA (pre-miR-302)” and the other is “RNA-dependent RNA polymerase (RdRp)” mRNA. Both of pre-miR-302 and RdRp mRNA contain highly structured RNA comformations, such as hairpins and stem- loops.
- a novel PCR-IVT methodology has been developed and used with a specially designed RNA polymerase-helicase mixture activity.
- iPS cells or iPSCs Induced pluripotent stem cells (iPS cells or iPSCs) were first reported by Yamanaka et al. in 2006, using three or four different protein transcription factors (U.S. Patents No. 8,048,999 and No. 8,058,065 to Yamanaka et al.; Takahashi K and Yamanaka S, Cell 126:663-676, 2006).
- Lin et al. first used microRNA (miRNA) miR-302 to reprogram human somatic cells into iPSCs in 2007 (European Patent No. EP2198025B1 and Ll.S. Patent No. 9,567,591 to Lin et al.). Using miR-302, Lin et al.
- miR-302 concentration level required for achieving complete iPSC formation is about >1.1-1.3 folds of that level found in human embryonic stem cell (ESC) lines WA01-H1 or WA09-H9.
- ESC human embryonic stem cell
- miR-369 or miR-367 may be needed for enhancing the reprogramming efficiency (Miyoshi et al., Cell Stem Cell 8:633-638, 2011; Anokye-Danso et al., Cell Stem Cell 8:376-388, 2011).
- miR-367 and miR-369 can also silence some human tumor-suppressor genes, such as p57(kip2) and p63, the resulting iPSCs often show higher tumorigenecity than that of iPSCs reprogrammed by using only miR-302.
- a method of increasing the delivery and/or reprogramming efficiency or raising the intracellular miR-302 expression level is highly desirable for overcoming such a tumorigenecity problem.
- RNA-IVT polymerase chain reaction and in vitro transcription
- Lin methods first use PCR and/or reverse transcription (RT) to incorporate a specific RNA promoter-primer into the resulting PCR products in order to generate promoter-driven DNA templates for IVT.
- RT reverse transcription
- an IVT reaction is performed to produce and amplify desired RNA molecules from the DNA templates (Lin et al, Methods Mol Biol. 221:93-101, 2003).
- This PCR-IVT reaction can be reiterated multiple cycles for further amplifying the desired RNA molecules.
- the desired RNAs can be transfected into targeted cells to generate piwi-interacting RNAs (piRNA) for silencing certain specific genes (U.S. Patents No. 8,372,969 and 8,609,831 to Lin et al.).
- Lin’s methods had been successfully used to produce mRNAs and piRNAs for eliciting at least a specific biological and/or gene silencing effect, these mRNAs and piRNAs so produced are not highly structured RNAs. Therefore, Lin’s PCR-IVT methods did not disclose an effective way to overcome the low efficiency problem of highly structured RNA prodution in vitro.
- RNAs may contain one or multiple hairpin-like stem-loop structures, including pre-miR-302 cluster RNAs.
- the present invention is a method of inducing and enhancing induced pluripotent stem cell (iPSC) generation using a novel mechanism of intracellular miR-302 precursor RNA (pre-miR-302) generation stimulated by an artificially added RNA-dependent RNA polymerase (RdRp) amplification activity.
- the RdRp is preferably isolated and/or modified from RNA viruses, such as coronavirus and/or hepatitis C virus. Since using conventional transfection methods is difficult to deliver sufficient pre-miR-302 required for achieving complete reprogramming of somatic cells to form iPSCs, the present invention herein adopts a novel intracellular RdRp-mediated amplification mechanism to overcome this tranfection/delivery problem.
- the same RdRp-mediated RNA amplification mechanism can be used to produce and amplify other various kinds of pre-miRNAs and mRNAs carrying at least an RdRp binding site, particularly viral, pathogenic antigen RNAs and/or known functional RNAs/mRNAs, which are useful for developing anti-viral and/or anti-disease/-cancer vaccines and medicines.
- miR-302 is one of major standard embryonic stem cell (ESC) markers exclusively expressed in pluripotent stem cells, such as human ESCs and iPSCs.
- ESC embryonic stem cell
- RdRp mainly exists in RNA viruses and is required for RNA viral multiplication. Hence, under a natural condition, reprogramming can not occur in somatic cells even after infected by RNA viruses.
- the present invention first discloses that somatic cell reprogramming can easily occur when the somatic cells are pre-transfected with a specially designed pre-miR-302 construct before RNA viral infection.
- viral RdRp does not randomly amplify all intracellular RNAs at the same rate, but more preferably amplifies those RNAs carrying at least an RdRp-binding site, such as viral RNAs. This amplification rate difference can be over several hundred to thousand folds.
- our designed pre-miR-302 constructs herein carry at least an isolated RdRp-binding site.
- RdRp amplifies the designed pre-miR-302 constructs over forty to thousand folds in the transfected cells, resulting in a marked increase of intracellular miR-302 concentration, of which the level is sufficient for inducing and enhancing complete iP SC generation.
- pre-miR-302 constructs contain at least a hairpin-like miR-302 precursor (pre-miR-302) sequence flanked with at least an RdRp binding site (equivalent to promoter and/or enhancer) in its either 5’-end or 3’-end region, or both.
- RdRp binding site equivalent to promoter and/or enhancer
- the designed pre-miR-302 construct in order to efficiently initiate the desired RdRp activity, the designed pre-miR-302 construct must contain at least a 5’ -end forward RdRp initiation/binding site or at least a 3’ -end reverse RdRp initiation/binding site, or both.
- the 5’ -end RdRp initiation/binding site contains at least a sequence of either 5’-AU(G/C)(U/-)G(A/U)-3’ (i.e. 5’-AUSUGW-3’; SEQ.ID.NO.l) or 5’- U(C/-)(U/A)C(U/C)(U/A)A-3 ’ (i.e. 5’-UCWCYWA-3’; SEQ.ID.NO.2), or both.
- the 5’-end RdRp initiation/binding site is preferably selected from at least a sequence containing 5’-AUCUGU-3’ (SEQ.ID.NO.3), 5’-UCUCUAA-3’ (SEQ.ID.NO.4), 5’- UCUCCUA-3’ (SEQ.ID.NO.5), and/or 5’-UUCAA-3’ (SEQ.ID.N0.6), or a combination thereof.
- the 3’ -end RdRp initiation/binding site contains at least a sequence of either 5’-(U/A)C(A/-)(C/G)AU-3’ (i.e.
- the 3’-end RdRp initiation/binding site is preferably selected from at least a sequence containing 5’-ACAGAU-3’ (SEQ.ID.N0.9), 5’-UUAGAGA-3’ (SEQ.ID.NO.10), 5 ’ -UAGGAGA-3 ’ (SEQ.ID.NO.il), and/or 5’-UUGAA-3’ (SEQ.ID.NO.12), or a combination thereof.
- RdRp initiation/binding sites were exclusively identified by the inventors of the present invention. Due to this special novel design, the desired RdRp activity can efficiently transcribe and amplify either the sense or antisense strand, or both, of the designed pre-miR-302 constructs in cells in vitro, ex vivo as well as in vivo.
- the specially designed RNA i.e, pre-miR-302 and/or RdRp mRNA, or other RNAs/mRNAs
- the specially designed RNA contains at least an RdRp-binding site in both of its 5’- and 3’ -end regions.
- the sense strand RNA can be used to amplify its complementary antisense RNAs (cRNA or aRNA), while the antisense strand RNA can be used to amplify the sense RNAs as well, so as to form an amplification cycle of both of the sense and antisense strand RNAs and thus resulting in a maximal amplification rate of the designed RNA construct.
- cRNA or aRNA complementary antisense RNAs
- the resulting sense and antisense strands of amplified RNAs may further form double-stranded RNAs in cells after transfection, facilitating the formation of siRNAs, shRNAs, miRNAs, and/or piRNAs of the designed RNA construct.
- the specially designed RNA construct contains at least an RdRp-binding site in its either 5’-end or 3’-end region.
- this approach is useful for generating and amplifying either the mRNA or the antisense RNA (aRNA) of a specific functional protein in cells after transfection, so as to either produce/increase or inhibit/decrease the generation of the functional protein in the transfected cells.
- the designed pre-miR-302 constructs may contain one or more hairpin-like miR-302 precursor sequences preferably selected from 5’-CCUUUGCUUU AACAUGGGGG UACCUGCUGU GUGAAACAAA AGUAAGUGCU UCCAUGUUUC AGUGGAGG-3’ (68-nt; SEQ.ID.N0.13), 5’-GCUCCCUUCA ACUUUAACAU GGAAGUGCUU UCUGUGACUU UAAAAGUAAG UGCUUCCAUG UUUUAGUAGG AGU-3’ (73-nt; SEQ.ID.N0.14), 5’-CCACCACUUA AACGUGGAUG UACUUGCUUU GAAACUAAAG AAGUAAGUGC UUCCAUGUUU UGGUGAUGG-3 ’ (69-nt;
- miR-302 precursor sequences there may further contain a 50 ⁇ 500-nucleotide spacer sequence for preventing hairpin tangle formation.
- these miR-302 precursor sequences can be replaced by miR-302-mimic short-interfering RNA (siRNA) and/or small hairpin RNA (shRNA) sequences for eliciting the same functional purpose.
- the uridine (U) content of these sequences can be replcaed by pseudouridine and/or other modified nucleotides to increase the stability of the designed pre-miR-302 constructs as well as RdRp mRNA.
- the present invention adopts a novel IVT system with a mixture of RNA polymerase and helicase activities.
- the addition of helicase activity in IVT markedly reduces the secondary structures of both DNA templates and the resulting RNA products for far more efficiently producing highly structured RNAs. Accordingly, an improved buffer system is also required to maintain and enhance the efficiency of mixed RNA polymerase and helicase activities in IVT.
- the present invention demonstrates a totally different functionality of helicase in RNA production during IVT.
- the specially designed pre-miR-302 construct and RdRp mRNA can be mixed, conjugated, encapsulated and/or formulated with at least a delivery/transfection agent selected from, but not limited to, glycylglycerin-derived chemicals, liposomes, nanoparticles, liposomal nanoparticles (LNP), conjugating molecules, infusion/transfusion chemicals, gene gun materials, electroporation agents, transposons/retrotransposons, and a combination thereof.
- a delivery/transfection agent selected from, but not limited to, glycylglycerin-derived chemicals, liposomes, nanoparticles, liposomal nanoparticles (LNP), conjugating molecules, infusion/transfusion chemicals, gene gun materials, electroporation agents, transposons/retrotransposons, and a combination thereof.
- iPSCs will quickly form within one to two weeks, depending on the reprogrammed cell types, via an induced biological process called somatic cell reprogramming. Lin’s prior review article had already disclosed the underlying mechanism of this reprogramming event (Lin SL, Stem Cells 29:1645-1649, 2011).
- the cell types capable of being reprogrammed into iPSCs include but not limited to cell substrates containing normal human tissue cells, somatic cells, diseased cells, tumor/cancer cells, skin-content- associated cells, and/or blood-content-associated cells, and a combination thereof.
- the inventors had gathered evidence for the success of iPSC generation in six areas: (1) markedly increased miR-302 expression in reprogrammed cells after co-transfection of pre-miR-302 and RdRp mRNA (FIG.
- the advantages of using the designed pre-miR-302 and RdRp mRNA mixture composition to induce iPSC generation include (1) no transgenic concerns, (2) no ethical concerns, (3) tumor-free grade high safety, (4) easy handling and preparation, (5) >70% iPSC formation efficiency, (7) stable and fast reprogramming efficiency within 1 ⁇ 2 weeks, and (8) multiple applications for use in in-vitro, ex-vivo, and/or in-vivo cell reprogramming.
- the present invention may also be used to generate and expand adult stem cell (ASC) populations as well.
- ASC adult stem cell
- the present invention is useful for designing and developing new pharmaceutical and therapeutic applications or devices, such as cell-based and/or reprogramming-associated therapies as well as medicines.
- Nucleic Acid a polymer of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), either single or double stranded.
- Nucleotide a monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base.
- the base is linked to the sugar moiety via the glycosidic carbon (G carbon of the pentose) and that combination of base and sugar is a nucleoside.
- a nucleoside containing at least one phosphate group bonded to the 3' or 5' position of the pentose is a nucleotide.
- DNA and RNA are consisted of different types of nucleotide units called deoxyribonucleotide and ribonucleotide, respectively.
- Oligonucleotide a molecule comprised of two or more monomeric units of DNA and/or RNA, preferably more than three, and usually more than ten. An oligonucleotide longer than 13 nucleotide monomers is also called polynucleotiude. The exact size will depend on many factors, which in turn depends on the ultimate function or use of the oligonucleotide.
- the oligonucleotide may be generated in any manner, including chemical synthesis, DNA replication, RNA transcription, reverse transcription, or a combination thereof.
- Nucleotide Analog a purine or pyrimidine nucleotide that differs structurally from adenine (A), thymine (T), guanine (G), cytosine (C), or uracil (U), but is sufficiently similar to substitute for the normal nucleotide in a nucleic acid molecule.
- nucleic Acid Composition refers to an oligonucleotide or polynucleotide such as a DNA or RNA sequence, or a mixed DNA/RNA sequence, in either a single-stranded or a double-stranded molecular structure.
- Gene a nucleic acid composition whose oligonucleotide or polynucleotide sequence codes for an RNA and/or a polypeptide (protein).
- a gene can be either RNA or DNA.
- a gene may encode a non-coding RNA, such as small hairpin RNA (shRNA), microRNA (miRNA), rRNA, tRNA, snoRNA, snRNA, and their RNA precursors as well as derivatives.
- a gene may encode a protein-coding RNA essential for protein/peptide synthesis, such as messenger RNA (mRNA) and its RNA precursors as well as derivatives.
- mRNA messenger RNA
- a gene may encode a protein-coding RNA that also contains at least a microRNA or shRNA sequence.
- RNA Transcript an RNA sequence that is directly transcribed from a gene without any RNA processing or modification.
- Precursor messenger RNA primary RNA transcripts of a protein-coding gene, which are produced by eukaryotic type-II RNA polymerase (Ro ⁇ -P) machineries in eukaryotes through an intracellular mechanism termed transcription.
- a pre-mRNA sequence contains a 5’ -untranslated region (UTR), a 3’-UTR, exons and introns.
- Intron a part or parts of a gene transcript sequence encoding non-protein-reading frames, such as in-frame intron, 5’ -UTR and 3’ -UTR.
- Exon a part or parts of a gene transcript sequence encoding protein-reading frames
- cDNA such as cDNA for cellular genes, growth factors, insulin, antibodies and their analogs/homologs as well as derivatives.
- RNA messenger RNA
- mRNA messenger RNA
- RNA splicing machineries e.g. spliceosomes
- the peptides/proteins encoded by mRNAs include, but not limited, enzymes, growth factors, insulin, antibodies and their analogs/homologs as well as derivatives.
- cDNA Complementary DNA
- Sense a nucleic acid molecule in the same sequence order and composition as the homologous mRNA. The sense conformation is indicated with a “+”, “s” or “sense” symbol.
- Antisense a nucleic acid molecule complementary to the respective mRNA molecule.
- the antisense conformation is indicated as a symbol or with an "a” or “antisense” in front of the DNA or RNA, e.g., "aDNA” or "aRNA”.
- Base Pair a partnership of adenine (A) with thymine (T), or of cytosine (C) with guanine (G) in a double stranded DNA molecule.
- RNA uracil
- U uracil
- the partnership is achieved through hydrogen bonding.
- a sense nucleotide sequence "5’-A-T-C-G-U-3’" can form complete base pairing with its antisense sequence "5’-A-C-G-A-T-3’”.
- 5 ’-end a terminus lacking a nucleotide at the 5’ position of successive nucleotides in which the 5’-hydroxyl group of one nucleotide is joined to the 3’-hydroyl group of the next nucleotide by a phosphodiester linkage.
- Other groups, such as one or more phosphates, may be present on the terminus.
- 3 ’-end a terminus lacking a nucleotide at the 3’ position of successive nucleotides in which the 5’-hydroxyl group of one nucleotide is joined to the 3’-hydroyl group of the next nucleotide by a phosphodiester linkage.
- Other groups, most often a hydroxyl group, may be present on the terminus.
- Template a nucleic acid molecule being copied by a nucleic acid polymerase.
- a template can be single-stranded, double-stranded or partially double-stranded, RNA or DNA, depending on the polymerase.
- the synthesized copy is complementary to the template, or to at least one strand of a double-stranded or partially double-stranded template.
- Both RNA and DNA are synthesized in the 5' to 3' direction.
- the two strands of a nucleic acid duplex are always aligned so that the 5' ends of the two strands are at opposite ends of the duplex (and, by necessity, so then are the 3' ends).
- Nucleic Acid Template a double-stranded DNA molecule, double-stranded RNA molecule, hybrid molecules such as DNA-RNA or RNA-DNA hybrid, or single-stranded DNA or RNA molecule.
- Homologous or Homology a term indicating the similarity between a polynucleotide and a gene or mRNA sequence.
- a nucleic acid sequence may be partially or completely homologous to a particular gene or mRNA sequence, for example.
- Homology may be expressed as a percentage determined by the number of similar nucleotides over the total number of nucleotides.
- Complementary or Complementarity or Complementation a term used in reference to matched base pairing between two polynucleotides (i.e. sequences of an mRNA and a cDNA) related by the aforementioned “base pair (bp)” rules.
- base pair bp
- the sequence “5’-A-G-T- 3’” is complementary to not only the sequence “5’-A-C-T-3’” but also to "5’-A-C-U-3’”.
- Complementation can be between two DNA strands, a DNA and an RNA strand, or between two RNA strands. Complementarity may be "partial” or "complete” or “total”.
- Partial complementarity or complementation occurs when only some of the nucleic acid bases are matched according to the base pairing rules. Complete or total complementarity or complementation occurs when the bases are completely or perfectly matched between the nucleic acid strands.
- the degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as in detection methods that depend on binding between nucleic acids.
- Percent complementarity or complementation refers to the number of mismatch bases over the total bases in one strand of the nucleic acid. Thus, a 50% complementation means that half of the bases were mismatched and half were matched. Two strands of nucleic acid can be complementary even though the two strands differ in the number of bases. In this situation, the complementation occurs between the portion of the longer strand corresponding to the bases on that strand that pair with the bases on the shorter strand.
- Complementary Bases nucleotides that normally pair up when DNA or RNA adopts a double stranded configuration.
- Complementary Nucleotide Sequence a sequence of nucleotides in a single-stranded molecule of DNA or RNA that is sufficiently complementary to that on another single strand to specifically hybridize between the two strands with consequent hydrogen bonding.
- Hybridize and Hybridization the formation of duplexes between nucleotide sequences which are sufficiently complementary to form complexes via base pairing.
- a primer or splice template
- target template
- complexes or hybrids
- Posttranscriptional Gene Silencing a targeted gene knockout or knockdown effect at the level of mRNA degradation or translational suppression, which is usually triggered by either foreign/viral DNA or RNA transgenes or small inhibitory RNAs.
- RNA Interference a posttranscriptional gene silencing mechanism in eukaryotes, which can be triggered by small inhibitory RNA molecules such as microRNA (miRNA), small hairpin RNA (shRNA) and small interfering RNA (siRNA). These small RNA molecules usually function as gene silencers, interfering with expression of intracellular genes containing either completely or partially complementarity to the small RNAs.
- miRNA microRNA
- shRNA small hairpin RNA
- siRNA small interfering RNA
- Gene Silencing Effect a cell response after a gene function is suppressed, consisting but not limited of cell cycle attenuation, G0/G1 -checkpoint arrest, tumor suppression, anti- tumorigenecity, cancer cell apoptosis, and a combination thereof.
- Non-coding RNA an RNA transcript that cannot be used to synthesize peptides or proteins through intracellular translation machineries.
- Non-coding RNA includes long and short regulatory RNA molecules such as microRNA (miRNA), small hairpin RNA (shRNA), small interfering RNA (siRNA) and double strand RNA (dsRNA). These regulatory RNA molecules usually function as gene silencers, interfering with expression of intracellular genes containing either completely or partially complementarity to the non-coding RNAs.
- miRNA microRNA
- shRNA small hairpin RNA
- siRNA small interfering RNA
- dsRNA double strand RNA
- MicroRNA single-stranded RNAs capable of binding to targeted gene transcripts that have partial complementarity to the miRNA.
- MiRNA is usually about 17-27 oligonucleotides in length and is able to either directly degrade its intracellular mRNA target(s) or suppress the protein translation of its targeted mRNA, depending on the complementarity between the miRNA and its target mRNA.
- Natural miRNAs are found in almost all eukaryotes, functioning as a defense against viral infections and allowing regulation of gene expression during development of plants and animals.
- Precursor MicroRNA hairpin-like single-stranded RNAs containing stem-arm and stem-loop regions for interacting with intracellular RNaselll endoribonucleases to produce one or multiple microRNAs (miRNAs) capable of silencing a targeted gene or genes complementary to the microRNA sequence(s).
- the stem-arm of a pre-miRNA can form either a perfectly (100%) or a partially (mis-matched) hybrid duplexes, while the stem- loop connects one end of the stem-arm duplex to form a circle or hairpin-loop conformation.
- precursor of microRNA may also includes pri-miRNA.
- siRNA small interfering RNA: short double-stranded RNAs sized about 18-27 perfectly base-paired ribonucleotide duplexes and capable of degrading target gene transcripts with almost perfect complementarity.
- Small or short hairpin RNA single-stranded RNAs that contain a pair of partially or completely matched stem-arm nucleotide sequences divided by an unmatched loop or bubble oligonucleotide to form a hairpin-like structure.
- Many natural miRNAs are derived from small hairpin-like RNA precursors, namely precursor microRNA (pre-miRNA).
- Vector a recombinant nucleic acid composition such as recombinant DNA (rDNA) capable of movement and residence in different genetic environments. Generally, another nucleic acid is operatively linked therein.
- the vector can be capable of autonomous replication in a cell in which case the vector and the attached segment is replicated.
- One type of preferred vector is an episome, i.e., a nucleic acid molecule capable of extrachromosomal replication.
- Preferred vectors are those capable of autonomous replication and expression of nucleic acids.
- Vectors capable of directing the expression of genes encoding for one or more polypeptides and/or non-coding RNAs are referred to herein as “expression vectors” or “expression-competent vectors”.
- a vector may contain components consisting of a viral or a type-II RNA polymerase (Pol-II or pol-2) promoter, or both, a Kozak consensus translation initiation site, polyadenylation signals, a plurality of restriction/cloning sites, a pUC origin of replication, a SV40 early promoter for expressing at least an antibiotic resistance gene in replication-competent prokaryotic cells, an optional SV40 origin for replication in mammalian cells, and/or a tetracycline responsive element.
- the structure of a vector can be a linear or circular form of single- or double- stranded DNA selected form the group consisting of plasmid, viral vector, transposon, retrotransposon, DNA transgene, jumping gene, and a combination thereof.
- Promoter a nucleic acid to which a polymerase molecule recognizes, perhaps binds to, and initiates RNA transcription.
- a promoter can be a known polymerase binding site, an enhancer and the like, any sequence that can initiate synthesis of RNA transcripts by a desired polymerase.
- Restriction Site a DNA motif for restriction enzyme cleavage including but not limited Audi, Accl, AflII/III, Agel, Apal/LI, Asel, Asp718I, BamHI, Bbel, BclI/II, Bglll, Bsml, Bspl20I, BspHI/LUl 11/1201, BsrI/BI/GI, BssHII/SI, BstBI/Ul/XI, Clal, Csp6I, Dpnl, Dral/II, Eagl, Eel 13611, EcoRI/RIE47III/RV, Ehel, Fspl, Haelll, Hhal, HinPI, Hindlll, Hinfl, HpaEII, Kasl, Kpnl, Maell/III, Mfel, Mlul, Mscl, Msel, Nael, Narl, Ncol, Ndel, NgoMI, Notl, Nrul,
- Cistron a sequence of nucleotides in a DNA molecule coding for an amino acid residue sequence and including upstream and downstream DNA expression control elements.
- RNA Processing a cellular mechanism responsible for RNA maturation, modification and degradation, including RNA splicing, intron excision, exosome digestion, nonsense- mediated decay (NMD), RNA editing, RNA processing, 5’ -capping, 3’-poly(A) tailing, and a combination thereof.
- NMD nonsense- mediated decay
- Gene Delivery a genetic engineering method selected from the group consisting of polysomal transfection, liposomal transfection, chemical (nanoparticle) transfection, electroporation, viral infection, DNA recombination, transposon insertion, jumping gene insertion, microinjection, gene-gun penetration, and a combination thereof.
- Genetic Engineering a DNA recombination method selected from the group consisting of DNA restriction and ligation, homologous recombination, transgene incorporation, transposon insertion, jumping gene integration, retroviral infection, and a combination thereof.
- Tumor Suppression a cellular anti-tumor and anti-cancer mechanism consisting but not limited of cell cycle attenuation, G0/G1 -checkpoint arrest, tumor suppression, anti- turn origenecity, cancer cell apoptosis, and a combination thereof.
- Targeted Cell a single or a plurality of human cells selected from the group consisting of a somatic cell, a tissue cell, a stem cell, a germ-line cell, a tumor cell, a cancer cell, a virus- infected cell, and a combination thereof.
- Cancerous Tissue a neoplastic tissue derived from the group consisting of skin cancer, prostate cancer, breast cancer, liver cancer, lung cancer, brain tumor/cancer, lymphoma, leukemia and a combination thereof.
- Antibody a peptide or protein molecule having a pre-selected conserved domain structure coding for a receptor capable of binding a pre-selected ligand.
- compositions useful for stem cell generation, stem cell research and/or therapy development, cancer therapy, disease treatment, wound healing and tissue regeneration treatment, high- yield production of drug and/or food supplies, and a combination thereof.
- Prokaryote or Prokaryotic Cell an one-cell organism that lacks a distinct membrane- bound nucleus and has its genetic materials in the form of a continuous strand of DNA, such as bacteria.
- Eukaryote or Eukaryotic Cell an one-cell or multiple-cell organism whose cells contain a nucleus and other structures (organelles) enclosed within membranes, such as yeast, plant and animal cells.
- Transcription Inducer a chemical agent that can induce and/or enhance eukaryotic RNA and/or gene transcription from a eukaryotic pol-2 or pol-2 equivalent promoter in prokaryotic cells.
- a transcription inducer contains, but not limited, a chemical structure similar to 3 -morpholinopropane-1 -sulfonic acid (MOPS), ethanol and/or glycerin, as well as their functional analogs, such as mannitol, 2-(N-morpholino)ethanesulfonic acid (MES) and 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES), or a mixture thereof.
- MOPS 3 -morpholinopropane-1 -sulfonic acid
- MES 2-(N-morpholino)ethanesulfonic acid
- HEPES 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid
- a novel RNA composition and its production method for use in induced pluripotent stem cell (iPSC) generation comprising: at least a miR-302 precursor RNA (pre-miR-302) construct and at least an RNA- dependent RNA polymerase (RdRp) mRNA, wherein the pre-miR-302 construct contains at least a 5’ -end RdRp binding site or at least a 3’ -end RdRp binding site, or both, and wherein the RdRp mRNA is isolated and/or modified from RNA virus, preferably from coronavirus or hepatitis C virus.
- iPSC induced pluripotent stem cell
- the 5’ -end RdRp binding site contains at least a sequence of either 5’- AU(G/C)(U/-)G(A/U)-3 ’ (5’-AUSUGW-3’; SEQ.ID.NO.l) or 5’-U(C/-
- the 5’- end RdRp binding site is preferably selected from at least an RNA sequence containing 5’- AUCUGU-3’ (SEQ.ID.NO.3), 5’-UCUCUAA-3’ (SEQ.ID.NO.4), 5’-UCUCCUA-3’ (SEQ.ID.NO.5), and/or 5’-UUCAA-3’ (SEQ.ID.NO.6), or a combination thereof.
- the 3’ -end RdRp binding site contains at least a sequence of either 5’-(U/A)C(A/- )(C/G)AU-3’ (5’-WCASAU-3’; SEQ.ID.N0.7) or 5 -U( A/U)( A/G)G( A/U)(G/-) A-3 (5’- UWRGWR-3’; SEQ.ID.NO.8), or both.
- the 3’-end RdRp binding site is preferably selected from at least an RNA sequence containing 5’-ACAGAU-3’ (SEQ.ID.NO.9), 5 ’ -UUAGAGA-3 ’ (SEQ.ID.NO.10), 5’-UAGGAGA-3’ (SEQ.ID.NO.i l), and/or 5’-UUGAA-3’ (SEQ.ID.NO.12), or a combination thereof.
- the pre-miR-302 construct contains at least a hairpin-like miR-302 precursor sequence preferably selected from 5’-CCUUUGCUUU AACAUGGGGG UACCUGCUGU GUGAAACAAA AGUAAGUGCU UCCAUGUUUC AGUGGAGG-3’ (SEQ.ID.NO.13), 5’-GCUCCCUUCA ACUUUAACAU GGAAGUGCUU UCUGUGACUU UAAAAGUAAG UGCUUCCAUG UUUUAGUAGG AGU-3’ (SEQ.ID.NO.14), 5’- CCACCACUUA AACGUGGAUG UACUUGCUUU GAAACUAAAG AAGUAAGUGC UUCCAUGUUU UGGUGAUGG-3 ’ (SEQ.ID.NO.15), and/or 5’-CCUCUACUUU AACAUGGAGG CACUUGCUGU GACAUGACAA AAAUAAGUGC UUCCAUGUUU GAGUGUGG-3’ (SEQ.ID.NO.16
- miR- 302 precursor sequences there may further contain a 50 ⁇ 500-nucleotide spacer sequence for preventing hairpin tangle formation.
- these miR-302 precursor sequences can be replaced by using miR-302-mimic siRNA and/or shRNA sequences for eliciting the same cell reprogramming functionality.
- the uridine (U) content of these RNA sequences can be further replcaed by pseudouridine and/or other modified nucleotides to increase the stability of the pre-miR-302 construct.
- the pre-miR- 302 and RdRp mRNA are preferably produced using a novel PCR-IVT methodology with an RNA polymerase-helicase mixture activity and an improved buffer system.
- the design pre-miR-302 and RdRp mRNA mixture composition can be further mixed, conjugated, encapsulated and/or formulated with at least a delivery agent selected from glycylglycerins, liposomes, nanoparticles, liposomal nanoparticles (LNP), conjugating molecules, infusion chemicals, gene gun materials, transposons, electroporation agents, and a combination thereof.
- FIG. 1 depicts the step-by-step procedure of the PCR-IVT methodology.
- a part or whole procedure of this PCR-IVT method can be adopted for either single or multiple cycle amplification of desired RNA products.
- FIG. 2 depicts one of the preferred designs of the miR-302 precursor RNA (pre-miR- 302) construct.
- At least an RNA-dependent RNA polymerase (RdRp)-binding site or more can be placed in either 5’ -end or 3’ -end region, or both, of the pre-miR-302 construct.
- FIG. 3 shows markedly increased expressions of miR-302s ⁇ i.e. top to bottom: b, c, d, a) and RdRp mRNA in reprogrammed cells after co-transfection of both pre-miR-302 and RdRp mRNA (right) compared to that of transfection of only pre-miR-302 (middle), using Northern blot analysis.
- FIG. 4 shows elevated expression of standard embryonic stem cell (ESC) markers such as Oct3/4, Sox2 and Nanog found in reprogrammed cells three days after co-transfection of pre-miR-302 and RdRp mRNA, using Western blot analysis.
- ESC embryonic stem cell
- FIG. 5 shows iPSC-derived embryoid body formation after co-transfection of pre- miR-302 and RdRp mRNA.
- FIG. 6 shows global genomic DNA demethylation observed in the reprogrammed cells, similar to the status of human ESC genome.
- FIG. 7 shows >92% high similarity of genome-wide gene expression patterns compared to those of human ESC WA01 (HI) and WA09 (H9) cell lines, using microarray analysis.
- FIG. 8 shows iPSC-derived teratoma formation containing tissues derived from all three embryonic germ layers (ectoderm, mesoderm and definitive endoderm), using immunohisto-chemical staining with respective tissue cell markers.
- Starting tissue cells can be obtained from either enzymatically dissociated skin cells using Aasen’s protocol ⁇ Nat. Protocols 5, 371-382, 2010) or simply from the buffy coat fraction of heparin-treated peripheral blood cells.
- the isolated tissue samples must be kept fresh and used immediately by mixing with 4 mg/mL collagenase I and 0.25% TrypLE for 15-45 min, depending on cell density, and rinsed by HBSS containing trypsin inhibitor two times and then transferred to a new sterilized microtube containing 0.3 mL of feeder-free SFM culture medium (IrvineScientific, CA).
- cells were further dissociated by shaking in a microtube incubator for 1 min at 37°C and then transferred the whole 0.3 mL cell suspension to a 35-mm Matrigel-coated culture dish containing 1 mL of feeder-free SFM culture medium supplemented with formulated pre-miR-302+RdRp mRNA mixture, LIF, and bFGF/FGF2, or other optional defined factors.
- the used concentrations of pre-miR- 302+RdRp mRNA mixture, LIF, bFGF/FGF2, and other optional defined factors is ranged from 0.1 to 500 microgram (pg)/mL, respectively, in the cell culture medium.
- the cell culture medium and all of the supplements must be refreshed every 2 ⁇ 3 days and the cells are passaged at about 50% ⁇ 60% confluence by exposing the cells to trypsin/EDTA for 1 min and then rinsing two times in HBSS containing trypsin inhibitor.
- the cells were replated at 1:5-1:500 dilution in fresh feeder-free MSC Expansion SFM culture medium supplemented with formulated pre-miR-302+RdRp mRNA mixture, LIF, bFGF/FGF2, and/or other optional defined factors.
- keratinocytes For culturing keratinocytes, cells are isolated from skin tissues and cultivated in EpiLife serum-free cell culture medium supplemented with human keratinocyte growth supplements (HKGS, Invitrogen, Carlsbad, CA) in the presence of proper antibiotics at 37°C under 5% CO2. Culture cells are passaged at 50%-60% confluency by exposing cells to trypsin/EDTA solution for 1 min and rinsing once with phenol red-free DMEM medium (Invitrogen), and the detached cells are replated at 1:10 dilution in fresh EpiLife medium with HKGS supplements.
- HKGS human keratinocyte growth supplements
- iPSCs Human cancer and normal cell lines A549, MCF7, PC3, HepG2, Colo-829 and BEAS-2B were obtained either from the American Type Culture Collection (ATCC, Rockville, MD) or our collaborators and then maintained according to manufacturer’s or provider’s suggestions. After reprogramming, the resulting iPS cells (iPSCs) were cultivated and maintained following either Lin’s feeder-free or Takahashi’s feeder-based iPSC culture protocols (Lin et al., RNA 14:2115-2124, 2008; Lin et al., Nucleic Acids Res. 39:1054-1065, 2011; Takahashi K and Yamanaka S, Cell 126:663- 676, 2006). 2. In-Vitro RNA Transfection
- RNA transfection For RNA transfection, 0.5-500 pg of isolated pre-miR-302 and RdRp mRNA mixture (ratio ranged from about 20:1 to 1:20) is dissolved in 0.5 ml of fresh cell culture medium and mixed with 1-50 m ⁇ of In-VivoJetPEI or other similar transfection reagents. After 10-30 min incubation, the mixture is then added into a cell culture containing 50%-60% confluency of the cultivated cells. The medium is reflashed every 12 to 48 hours, depending on cell types. This transfection procedure may be performed repeatedly to increase transfection efficiency. The transfection results are further analyzed by various detection methods and shown in FIG. 3 to FIG. 8, respectively.
- Genomic DNAs were isolated from about two million cells with a Roche DNA isolation kit (Sigma-Aldrich, MO, USA). About 2 microgram (pg) of the isolated genomic DNAs was digested with a CCGG-cutting restriction enzyme, Hpall , and then assessed with 1% agarose gel electrophoresis to determine genome-wide demethylation (FIG. 4).
- RNAs from each tested sample were isolated using RNeasy spin columns (Qiagen, MD). To prepare labeled probes for microarray hybridization, the extracted total RNAs (2 pg) were converted into cDNAs, using a T7 promoter-containing oligo(dT)24 primer and Superscript double-stranded cDNA synthesis kit (ThermoFisher Scientific, MA), following manufacturer’s protocols.
- the resulting cDNAs were purified by phenol-chloroform extractions, precipitated with ethanol, and resuspended at a concentration of 0.5 pg/m ⁇ in diethyl pyrocarbonate (DEPC)-treated ddFFO. Then, in-vitro transcription was performed, containing 1 pg of the dsDNAs, 7.5 mM unlabeled ATP and GTP, 5 mM unlabeled UTP and CTP, and 2 mM biotin-labeled CTP and UTP (biotin- 11-CTP, biotin- 16-UTP, Enzo Diagnostics), and 20 U of T7 RNA polymerase.
- DEPC diethyl pyrocarbonate
- cRNAs were purified by RNeasy spin columns (Qiagen). A part of the cRNA sample was separated on a 1% agarose gel to check the size range, and then 10 pg of the cRNAs were fragmented randomly to an average size of 50 bases by heating at 94°C for 35 min in 40 mM Tris-acetate, pH 8.0, 100 mM KOAc/30 mM MgOAc. Hybridizations were completed in 200 pi of AFFY buffer (Affymetrix, CA) at 40°C for 16 hours with constant mixing.
- AFFY buffer Affymetrix, CA
- arrays were rinsed three times with 200 pi of 6x SSPE-T buffer (lx 0.25 M sodium chloride/15 mM sodium phosphate, pH 7.6/1 mM EDTA/0.005% Triton) and then washed with 200 pi of 6x SSPE-T for 1 hour at 50°C. The arrays were further rinsed twice with 0.5X SSPE-T and washed with 0.5x SSPE-T at 50°C for 15 min.
- 6x SSPE-T buffer lx 0.25 M sodium chloride/15 mM sodium phosphate, pH 7.6/1 mM EDTA/0.005% Triton
- staining assays were done with 2 pg/ml streptavidin-phycoerythrin (Invitrogen) and 1 mg/ml acetylated BSA (Sigma-Aldrich) in 6x SSPE-T (pH 7.6).
- the arrays were read at 7.5 pm with a confocal scanner (Molecular Dynamics).
- mice were made by intraperitoneally injection of 1 IU human menopausal gonadotrophin (HMG) for two days and then human chorionic gonadotrophin (hCG) for one more day.
- HMG menopausal gonadotrophin
- hCG human chorionic gonadotrophin
- iPS cells were maintained on polyornithine/ laminin-coated dishes in DMEM/F12 (1:1; high glucose) medium supplemented with charcoal-stripped 10% FBS, 4 mM L-glutamine, 1 mM sodium pyruvate, 5 ng/ml activin and 50 ng/ml dihydrotestosterone (DHT) for 12 hours, at 37°C under 5% CO2.
- mice were trypsinized, washed with lx PBS, and collected in four aliquots of chilled Matrigel (100 m ⁇ each) and one aliquots of 100 m ⁇ lx PBS.
- Matrigel subcutaneous neck skin
- PBS tail vein
- RT Reverse transcription
- mRNA RNA
- pg ng ⁇ 10 microgram
- RT reaction mixture contains the mRNA, about 0.01-20 nmole RT primer, a proper amount of dNTPs and reverse transcriptase in lx RT buffer.
- the RT reaction is incubated at 46 ⁇ 65°C for 1-3 hours (hr), depending on the structure and length of the desired mRNA, so as to make at least a complementary DNA (cDNA) template for the next step of PCR.
- cDNA complementary DNA
- PCR polymerase chain reaction
- RNA promoter-containing RdRp cDNA templates from coronaviral mRNA, including SEQ.ID.NO.17 and 5’- GATATCTAAT ACGACTCACT AT AGGGAGAG GTATGGTACT TGGTAGTT-3’ (SEQ.ID.NO.18).
- a 5’-cap nucleotide may be further incorporated in the resulting mRNA products during or after IVT.
- RNA promoter sequences can be used, such as T7, T3 and/or SP6 promoter, and at least a RdRp initiation/binding site has been incorporated in the 5’-forward and 3’-reverse primer sequences, respectively.
- the resulting miR-302 familial cluster template contains the cDNA sequences of at least one pre- miR-302a (SEQ.ID.NO.13), pre-miR-302b (SEQ.ID.NO.14), pre-miR-302c (SEQ.ID.NO.15), and/or pre-miR-302d (SEQ.ID.NO.16).
- the IVT reaction mixture contains 0.01 ng ⁇ 10 pg of the PCR product, 0.1-10 U of isolated coronaviral helicase (i.e. from COVID-19), a proper amount of NTPs and RNA polymerase (i.e. T7, T3, or SP6) in lx transcription buffer.
- lx transcription buffer may be adjusted according to the used RNA polymerase, following the manufacturer’s suggestions. Additionally, the lx transcription buffer may further conatin 0.001-10 mM of betaine (trimethylglycine, TMG), dimethylsulfoxide (DMSO), and/or 3-(N-morpholino)propane sulfonic acid (MOPS), and/or a combination thereof, which facilitates the denaturation of highly structured RNA/DNA sequences, such as hairpins and stem-loop structures. Then, the IVT reaction is incubated at 37°C for 1-6 hr, depending on the stability and activity of the used RNA polymerase(s).
- betaine trimethylglycine
- DMSO dimethylsulfoxide
- MOPS 3-(N-morpholino)propane sulfonic acid
- At least an additional helicase enzyme is added in order to facilitate the unwinding of RNA/DNA secondary structures, such as hairpin-like stem-loop structures, so as to overcome the low efficiency problem of hairpin-like RNA production in vitro.
- the helicase enyme can unwind the secondary structures in both DNA and RNA strands.
- Desired mRNAs (10 pg) are isolated with a mi W anaTM RNA isolation kit (Ambion, Austin, TX), following the manufacturer’s protocol, and then further purified by using either 15% TBE-urea polyacrylamide gel or 3.5% low melting point agarose gel electrophoresis.
- the gel -fractionated mRNAs are electroblotted onto a nylon membrane. Detection of the mRNA and its IVT template (the PCR product) is performed with a labeled [LNAJ-DNA probe complementary to a desired target sequence of the mRNA.
- the probe is further purified by high-performance liquid chromatography (HPLC) and tail- labeled with terminal transferase (20 units) for 20 min in the presence of either a dye-labeled nucleotide analog or [ 32 P]-dATP (> 3000 Ci/mM, Amersham International, Arlington Heights, IL).
- HPLC high-performance liquid chromatography
- Protein Extraction and Western Blot Analysis Cells (10 6 ) are lysed with a CelLytic-M lysis/extraction reagent (Sigma) supplemented with protease inhibitors, Leupeptin, TLCK, TAME and PMSF, following the manufacturer’s suggestion. Lysates are centrifuged at 12,000 rpm for 20 min at 4°C and the supernatant is recovered. Protein concentrations are measured using an improved SOFTmax protein assay package on an E-max microplate reader (Molecular Devices, CA).
- Each 30 pg of cell lysate are added to SDS-PAGE sample buffer under reducing (+50 mM DTT) and non-reducing (no DTT) conditions, and boiled for 3 min before loading onto a 6 ⁇ 8% polyacylamide gel. Proteins are resolved by SDS-polyacrylamide gel electrophoresis (PAGE), electroblotted onto a nitrocellulose membrane and incubated in Odyssey blocking reagent (Li-Cor Biosciences, Lincoln, NB) for 2 hr at room temperature. Then, a primary antibody is applied to the reagent and incubated the mixture at 4°C.
- PAGE SDS-polyacrylamide gel electrophoresis
- the membrane is rinsed three times with TBS-T and then exposed to goat anti-mouse IgG conjugated secondary antibody to Alexa Fluor 680 reactive dye (1:2,000; Invitrogen-Molecular Probes), for 1 hr at the room temperature.
- fluorescent scanning of the immunoblot and image analysis are conducted using Li-Cor Odyssey Infrared Imager and Odyssey Software v.10 (Li-Cor).
- Isolated pre-miR-302 and RdRp mRNA mixture is mixed well with a proper amount of delivery agent, such as an In-VivoJetPEI transfection reagent, following the manufacturer’s protocol, and then injected into blood veins or muscles of an animal, depending the purpose of applications.
- the delivery agent is used for mixing, conjugating, encapsulating or formulating the isolated pre-miR-302 and RdRp mRNA mixture, so as to not only protect the RNA contents from degradation but also facilitate the delivery of the isolated pre-miR-302 and RdRp mRNA mixture into specific target cells of interest in vitro, ex vivo and/or in vivo. 11.
- Shi-Lung Lin and Ying SY Mechanism and method for generating tumor-free iPS cells using intronic microRNA miR302 induction. Shao-Yao Ying (Ed.) MicroRNA Protocols, 2nd Ed. Chapter 23, pp 295-324, Springer Publishers press, New York, 2012.. 18. Shi-Lung Lin: Deciphering the mechanism behind induced pluripotent stem cell generation. Stem Cells 29:1645-1649, 2011.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
This invention generally relates to a novel RNA composition and its production method useful for generating and expanding induced pluripotent stem cells (iPS cells; iPSC) as well as adult stem cells (ASC). The RNA composition so defined can be used for producing not only non-transgenic but also tumor-free iPS cells. The defined RNA composition contans at least two types of different RNA constructs; one is "miR-302 precursor RNA (pre-miR-302)" and the other is "RNA-dependent RNA polymerase (RdRp)" mRNA. Both of pre-miR-302 and RdRp mRNA contain highly structured RNA comformations, such as hairpin and stem-loop structures. To produce highly structured RNAs, a novel PCR-IVT methodology has been developed and used with a specially designed RNA polymerase-helicase mixture activity.
Description
TITLE: Novel RNA Composition and Production Method for Use in iPS Cell
Generation
CROSS-REFERENCE TO RELATED APPLICATIONS: The present invention claims priority to U.S. Provisional Patent Application No.
63/209,969 filed on June 12, 2021, which is entitled “Novel mRNA Composition and Production for Use in Anti -Viral and Anti-Cancer Vaccines”. The present invention also claims priority to U.S. Provisional Patent Applications No. 63/210,988 filed on June 15, 2021, No. 63/212,657 filed on June 19, 2021, and No. 63/222,398 filed on July 15, 2021, all of which are entitled “Novel mRNA Composition and Production Method for Use in Anti- Viral and Anti-Cancer Vaccines”. The present invention further claims priority to U.S. Provisional Patent Applications No. 63/270,034 filed on October 20, 2021, and No. 63/280,226 filed on November 17, 2021, both of which are entitled “Novel RNA Composition and Production Method for Use in iPS Cell Generation”. The present application is a continuation-in-part application of the U.S. Patent Application No. 17/489,357 filed on September 29, 2021, which is entitled “Novel mRNA Composition and Production Method for Use in Anti-Viral and Anti-Cancer Vaccines”. The contents of each application are hereby incorporated by reference in their entirety. FIELD OF INVENTION:
This invention generally relates to a novel RNA composition and its production method useful for generating and expanding induced pluripotent stem cells (iPS cells; iPSC) as well as adult stem cells (ASC). The RNA composition so defined can be used for producing not only non-transgenic but also tumor-free iPS cells. The defined RNA composition contans at
least two types of different RNA constructs; one is “miR-302 precursor RNA (pre-miR-302)” and the other is “RNA-dependent RNA polymerase (RdRp)” mRNA. Both of pre-miR-302 and RdRp mRNA contain highly structured RNA comformations, such as hairpins and stem- loops. To produce highly structured RNAs, a novel PCR-IVT methodology has been developed and used with a specially designed RNA polymerase-helicase mixture activity.
BACKGROUND:
Induced pluripotent stem cells (iPS cells or iPSCs) were first reported by Yamanaka et al. in 2006, using three or four different protein transcription factors (U.S. Patents No. 8,048,999 and No. 8,058,065 to Yamanaka et al.; Takahashi K and Yamanaka S, Cell 126:663-676, 2006). Alternatively, soon after that, Lin et al. first used microRNA (miRNA) miR-302 to reprogram human somatic cells into iPSCs in 2007 (European Patent No. EP2198025B1 and Ll.S. Patent No. 9,567,591 to Lin et al.). Using miR-302, Lin et al. generated tumor-free iPSCs from not only normal tissue cells but also cancerous cells (Lin et al., RNA 14:2115-2124, 2008; Lin et al., Cancer Res. 70:9473-9482, 2010; Lin et al., Nucleic Acids Res. 39:1054-1065, 2011; Lin SL and Ying SY, MicroRNA Protocols, 2nd Ed. Chapter 23, pp 295-324, Springer Publishers press, New York, 2012). Later in 2011, Lin et al. further revealed the mechanism underlying this miR-302-mediated somatic cell reprogramming event (Lin et al., Nucleic Acids Res. 39:1054-1065, 2011; Lin SL, Stem Cells 29: 1645-1649, 2011). In addition to Lin’s findings in 2011, two other independent research groups, Miyoshi et al. and Anokye-Danso et a!., also simultaneously confirmed the essential role of miR-302 in iPSC generation (Miyoshi et al., Cell Stem Cell 8:633-638, 2011; Anokye- Danso et al, Cell Stem Cell 8:376-388, 2011). Eventually, al! these major prior studies and inventions open up a whole new avenue for further research and development of many other following RNA-mediated iPSC technologies.
As demonstrated in the cited prior studies, Lin et al. had identified that the reprogramming efficiency of iPSC generation is determined by the intracellular levels of miR-302 concentration (Lin et al., Nucleic Acids Res. 39:1054-1065, 2011). The miR-302 concentration level required for achieving complete iPSC formation is about >1.1-1.3 folds of that level found in human embryonic stem cell (ESC) lines WA01-H1 or WA09-H9. However, the efficiency of current non-viral vector-based delivery of miR-302 or miR-302- mimic siRNA into somatic cells is hard to control and usually lower than the miR-302 concentration level required for achieving complete reprogramming. Hence, the addition of some other kinds of microRNAs like miR-369 or miR-367 may be needed for enhancing the reprogramming efficiency (Miyoshi et al., Cell Stem Cell 8:633-638, 2011; Anokye-Danso et al., Cell Stem Cell 8:376-388, 2011). Yet, because miR-367 and miR-369 can also silence some human tumor-suppressor genes, such as p57(kip2) and p63, the resulting iPSCs often show higher tumorigenecity than that of iPSCs reprogrammed by using only miR-302. As a result, a method of increasing the delivery and/or reprogramming efficiency or raising the intracellular miR-302 expression level is highly desirable for overcoming such a tumorigenecity problem.
Not only that, another problem of miR-302-mediated iPSC generation is due to the highly structured conformations of miR-302 precursor RNA (pre-miR-302), which is very difficult to be produced by using conventional enzymatic or machinery synthesis methods. Prior mRNA/pre-miRNA production methods are mainly dependent on polymerase chain reaction and in vitro transcription (PCR-IVT) (U.S. Patents No. 7,662,791, 8,080,652, 8,372,969, and 8,609,831 to Lin et al.); yet, these prior PCR-IVT methods are not designed to overcome the low production rate of highly structured RNAs. As depicted in FIG. 1, Lin’s methods first use PCR and/or reverse transcription (RT) to incorporate a specific RNA promoter-primer into the resulting PCR products in order to generate promoter-driven DNA
templates for IVT. Next, an IVT reaction is performed to produce and amplify desired RNA molecules from the DNA templates (Lin et al, Methods Mol Biol. 221:93-101, 2003). This PCR-IVT reaction can be reiterated multiple cycles for further amplifying the desired RNA molecules. After that, the desired RNAs can be transfected into targeted cells to generate piwi-interacting RNAs (piRNA) for silencing certain specific genes (U.S. Patents No. 8,372,969 and 8,609,831 to Lin et al.). Nevertheless, although Lin’s methods had been successfully used to produce mRNAs and piRNAs for eliciting at least a specific biological and/or gene silencing effect, these mRNAs and piRNAs so produced are not highly structured RNAs. Therefore, Lin’s PCR-IVT methods did not disclose an effective way to overcome the low efficiency problem of highly structured RNA prodution in vitro.
To solve the low efficiency problem of highly structured RNA production, another kind of methods using plasmid-driven RNA expression in prokaryotes (i.e. bacteria) had been developed by Lin et al. (U.S. Patents No. 9,637,747 and 9,783,811 to Lin et al.). These prokaryote-produced RNAs may contain one or multiple hairpin-like stem-loop structures, including pre-miR-302 cluster RNAs. In this approach, a chemical transcription inducer needs to be added into the medium of prokaryotic cell culture to overcome the problem of intrinsic transcription termination caused by hairpin RNAs (McDowell et al., Science 266:822-825, 1994), resulting in a marked increase of hairpin-like RNA production. Nevertheless, it is also noted that this plasmid-driven RNA expression methodology requires to use prokaryotic cells and the RNA production is limited in prokaryotes.
Since increasing the intracellular concentration of highly structured pre-miR-302 constructs for achieving high-throughput iPSC generation is one of key novelties of the present invention, it is herein rquired to have a methodology for not only overcoming the low efficiency problem of pre-miR-302 production but alo raising the delivery/reprogramming efficiency of pre-miR-302 in targeted cells. Unfortunately, none of prior PCR-IVT and
iPSC generation methods, not even in combination, can fulfill this goal. Therefore, a novel intracellular pre-miR-302 production method for inducing and enhancing iPSC generation is highly desired. SUMMARY OF THE INVENTION:
The present invention is a method of inducing and enhancing induced pluripotent stem cell (iPSC) generation using a novel mechanism of intracellular miR-302 precursor RNA (pre-miR-302) generation stimulated by an artificially added RNA-dependent RNA polymerase (RdRp) amplification activity. The RdRp is preferably isolated and/or modified from RNA viruses, such as coronavirus and/or hepatitis C virus. Since using conventional transfection methods is difficult to deliver sufficient pre-miR-302 required for achieving complete reprogramming of somatic cells to form iPSCs, the present invention herein adopts a novel intracellular RdRp-mediated amplification mechanism to overcome this tranfection/delivery problem. Due to this novel RdRp-mediated amplification mechanism, even only a small amount of delivered pre-miR-302 can be amplified at least forty to over thousand folds in the transfected cells, so as to provide sufficient intracellular pre-miR-302 concentrations for inducing and enhancing complete somatic cell reprogramming to form iPSCs. Conceivably, the same RdRp-mediated RNA amplification mechanism can be used to produce and amplify other various kinds of pre-miRNAs and mRNAs carrying at least an RdRp binding site, particularly viral, pathogenic antigen RNAs and/or known functional RNAs/mRNAs, which are useful for developing anti-viral and/or anti-disease/-cancer vaccines and medicines.
It is not reasonable for an ordinary skillful person in the art to anticipate the amplification of pre-miR-302 in somatic cells because somatic cells contain neither pre-miR-
302 nor RdRp. miR-302 is one of major standard embryonic stem cell (ESC) markers exclusively expressed in pluripotent stem cells, such as human ESCs and iPSCs. On the other hand, RdRp mainly exists in RNA viruses and is required for RNA viral multiplication. Hence, under a natural condition, reprogramming can not occur in somatic cells even after infected by RNA viruses. Yet, the present invention first discloses that somatic cell reprogramming can easily occur when the somatic cells are pre-transfected with a specially designed pre-miR-302 construct before RNA viral infection. During RNA viral infection, viral RdRp does not randomly amplify all intracellular RNAs at the same rate, but more preferably amplifies those RNAs carrying at least an RdRp-binding site, such as viral RNAs. This amplification rate difference can be over several hundred to thousand folds. Using the same mechanism, our designed pre-miR-302 constructs herein carry at least an isolated RdRp-binding site. In this way, RdRp amplifies the designed pre-miR-302 constructs over forty to thousand folds in the transfected cells, resulting in a marked increase of intracellular miR-302 concentration, of which the level is sufficient for inducing and enhancing complete iP SC generation.
The general structure of our specially designed pre-miR-302 constructs contain at least a hairpin-like miR-302 precursor (pre-miR-302) sequence flanked with at least an RdRp binding site (equivalent to promoter and/or enhancer) in its either 5’-end or 3’-end region, or both. As shown in FIG. 2, in order to efficiently initiate the desired RdRp activity, the designed pre-miR-302 construct must contain at least a 5’ -end forward RdRp initiation/binding site or at least a 3’ -end reverse RdRp initiation/binding site, or both. Before and after the initiation/binding sites, there may further contain a short about 1- to 55- nucleotide sequence of adenosine/uridine-rich (A/U-rich) motif, which is resulted from the desired RdRp extension activity. The 5’ -end RdRp initiation/binding site contains at least a sequence of either 5’-AU(G/C)(U/-)G(A/U)-3’ (i.e. 5’-AUSUGW-3’; SEQ.ID.NO.l) or 5’-
U(C/-)(U/A)C(U/C)(U/A)A-3 ’ (i.e. 5’-UCWCYWA-3’; SEQ.ID.NO.2), or both. For example, the 5’-end RdRp initiation/binding site is preferably selected from at least a sequence containing 5’-AUCUGU-3’ (SEQ.ID.NO.3), 5’-UCUCUAA-3’ (SEQ.ID.NO.4), 5’- UCUCCUA-3’ (SEQ.ID.NO.5), and/or 5’-UUCAA-3’ (SEQ.ID.N0.6), or a combination thereof. On the other hand, the 3’ -end RdRp initiation/binding site contains at least a sequence of either 5’-(U/A)C(A/-)(C/G)AU-3’ (i.e. 5’-WCASAU-3’; SEQ.ID.N0.7) or 5’- U(A/U)(A/G)G(A/U)(G/-)A-3’ (i.e. 5’-UWRGWR-3’; SEQ.ID.N0.8), or both. For example, the 3’-end RdRp initiation/binding site is preferably selected from at least a sequence containing 5’-ACAGAU-3’ (SEQ.ID.N0.9), 5’-UUAGAGA-3’ (SEQ.ID.NO.10), 5 ’ -UAGGAGA-3 ’ (SEQ.ID.NO.il), and/or 5’-UUGAA-3’ (SEQ.ID.NO.12), or a combination thereof. Notably, these defined RdRp initiation/binding sites were exclusively identified by the inventors of the present invention. Due to this special novel design, the desired RdRp activity can efficiently transcribe and amplify either the sense or antisense strand, or both, of the designed pre-miR-302 constructs in cells in vitro, ex vivo as well as in vivo.
In one preferred embodiment, the specially designed RNA (i.e, pre-miR-302 and/or RdRp mRNA, or other RNAs/mRNAs) construct contains at least an RdRp-binding site in both of its 5’- and 3’ -end regions. Since both ends of the designed RNA construct carry at least an RdRp-binding site for RNA amplification with RdRp, the sense strand RNA can be used to amplify its complementary antisense RNAs (cRNA or aRNA), while the antisense strand RNA can be used to amplify the sense RNAs as well, so as to form an amplification cycle of both of the sense and antisense strand RNAs and thus resulting in a maximal amplification rate of the designed RNA construct. Also, the resulting sense and antisense strands of amplified RNAs may further form double-stranded RNAs in cells after
transfection, facilitating the formation of siRNAs, shRNAs, miRNAs, and/or piRNAs of the designed RNA construct.
Alternatively, in another preferred embodiment, the specially designed RNA construct contains at least an RdRp-binding site in its either 5’-end or 3’-end region. In this way, we can selectively amplify either the sense or antisense strand of the designed RNA construct, leading to more specific amplification of the desired strand of the designed RNA construct. Particularly, this approach is useful for generating and amplifying either the mRNA or the antisense RNA (aRNA) of a specific functional protein in cells after transfection, so as to either produce/increase or inhibit/decrease the generation of the functional protein in the transfected cells.
Furthermore, the designed pre-miR-302 constructs may contain one or more hairpin-like miR-302 precursor sequences preferably selected from 5’-CCUUUGCUUU AACAUGGGGG UACCUGCUGU GUGAAACAAA AGUAAGUGCU UCCAUGUUUC AGUGGAGG-3’ (68-nt; SEQ.ID.N0.13), 5’-GCUCCCUUCA ACUUUAACAU GGAAGUGCUU UCUGUGACUU UAAAAGUAAG UGCUUCCAUG UUUUAGUAGG AGU-3’ (73-nt; SEQ.ID.N0.14), 5’-CCACCACUUA AACGUGGAUG UACUUGCUUU GAAACUAAAG AAGUAAGUGC UUCCAUGUUU UGGUGAUGG-3 ’ (69-nt;
SEQ.ID.NO.15), and/or 5’-CCUCUACUUU AACAUGGAGG CACUUGCUGU GACAUGACAA AAAUAAGUGC UUCCAUGUUU GAGUGUGG-3’ (68-nt; SEQ.ID.NO.16), or a combination thereof. Between two individual miR-302 precursor sequences, there may further contain a 50~500-nucleotide spacer sequence for preventing hairpin tangle formation. Conceivably, these miR-302 precursor sequences can be replaced by miR-302-mimic short-interfering RNA (siRNA) and/or small hairpin RNA (shRNA) sequences for eliciting the same functional purpose. Also, the uridine (U) content of these
sequences can be replcaed by pseudouridine and/or other modified nucleotides to increase the stability of the designed pre-miR-302 constructs as well as RdRp mRNA.
To efficiently produce these highly structured pre-miR-302 constructs and RdRp mRNA, we had developed a novel PCR-IVT methodology for overcoming the low efficiency problem of highly structured RNA generation (shown in U.S. Patent Application No. 17/489,357 to Lin et al.). Traditionally, it is not reasonable for an ordinary skillful person in the art to anticipate the efficient generation of highly structured RNAs in vitro because it is known that the presence of hairpin-like RNA structures greatly hinders RNA transcription. In fact, hairpin-like stem-loop structures are signals of intrinsic transcription termination for prokaryotic RNA polymerases (McDowell et al, Science 266:822-825, 1994). To solve this problem, the present invention adopts a novel IVT system with a mixture of RNA polymerase and helicase activities. The addition of helicase activity in IVT markedly reduces the secondary structures of both DNA templates and the resulting RNA products for far more efficiently producing highly structured RNAs. Accordingly, an improved buffer system is also required to maintain and enhance the efficiency of mixed RNA polymerase and helicase activities in IVT. Interestingly, although several prior studies had reported that helicase may be involved in prokaryotic transcription termination, the present invention however demonstrates a totally different functionality of helicase in RNA production during IVT.
For facilitating intracellular delivery/transfection in vitro, ex vivo or in vivo, the specially designed pre-miR-302 construct and RdRp mRNA can be mixed, conjugated, encapsulated and/or formulated with at least a delivery/transfection agent selected from, but not limited to, glycylglycerin-derived chemicals, liposomes, nanoparticles, liposomal nanoparticles (LNP), conjugating molecules, infusion/transfusion chemicals, gene gun materials, electroporation agents, transposons/retrotransposons, and a combination thereof.
After co-transfection of the designed pre-miR-302 construct and RdRp mRNA into desired target cells, iPSCs will quickly form within one to two weeks, depending on the reprogrammed cell types, via an induced biological process called somatic cell reprogramming. Lin’s prior review article had already disclosed the underlying mechanism of this reprogramming event (Lin SL, Stem Cells 29:1645-1649, 2011). In experiments, the inventors have already tested this novel reprogramming methodology in both human normal and cancerous somatic cells, including isolated normal fibroblasts, isolated normal skin cells (in vitro as well as ex vivo), isolated human leukemia cells, human lung epithelial cell line BEAS-2B as well as cancerous lung NSCLC A549, breast adenocarcinoma MCF7, prostate carcinoma PC3, liver hepatocarcinoma HepG2, and skin melanoma Colo-829 cell lines. Hence, in view of high genomic similarity of these various human cells, the cell types capable of being reprogrammed into iPSCs include but not limited to cell substrates containing normal human tissue cells, somatic cells, diseased cells, tumor/cancer cells, skin-content- associated cells, and/or blood-content-associated cells, and a combination thereof. Using the present invention, the inventors had gathered evidence for the success of iPSC generation in six areas: (1) markedly increased miR-302 expression in reprogrammed cells after co-transfection of pre-miR-302 and RdRp mRNA (FIG. 3), (2) elevated expression of standard ESC markers such as Oct3/4, Sox2 and Nanog found in reprogrammed cells 2~3 days after co-transfection of pre-miR-302 and RdRp mRNA (FIG. 4), (3) iPSC-derived embryoid body formation (FIG. 5), (4) global genomic DNA demethylation observed, similar to the status of a zygotic genome (FIG. 6), (5) over 92% high similarity of genome-wide gene expression patterns compared to those of human ESC WA01 (HI) and WA09 (H9) cell lines (FIG. 7), and (6) iPSC-derived teratoma formation containing tissues derived from all three embryonic germ layers (ectoderm, mesoderm and definitive endoderm) (FIG. 8). Furthermore, the inventors had also successfully used electroporation-based delivery methods
to achieve similar iPSC generation results. Given that the function of miR-302 is known to reprogram both normal and cancerous tissue cells to tumor-free ESC-like iPSCs with a high >70% success rate, the findings of this novel invention may provide great benefits for designing and developing advanced applications in both stem cell and anti-cancer therapies.
The advantages of using the designed pre-miR-302 and RdRp mRNA mixture composition to induce iPSC generation include (1) no transgenic concerns, (2) no ethical concerns, (3) tumor-free grade high safety, (4) easy handling and preparation, (5) >70% iPSC formation efficiency, (7) stable and fast reprogramming efficiency within 1~2 weeks, and (8) multiple applications for use in in-vitro, ex-vivo, and/or in-vivo cell reprogramming. Further in view of our prior U.S. Patent Applications No. 15/661,346 and No. 16/135,723 to Lin et ah, the present invention may also be used to generate and expand adult stem cell (ASC) populations as well. Conceivably, the present invention is useful for designing and developing new pharmaceutical and therapeutic applications or devices, such as cell-based and/or reprogramming-associated therapies as well as medicines.
A. Definitions
To facilitate understanding of the invention, a number of terms are defined below:
Nucleic Acid: a polymer of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), either single or double stranded.
Nucleotide: a monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via the glycosidic carbon (G carbon of the pentose) and that combination of base and sugar is a nucleoside. A nucleoside containing at least one phosphate group bonded to the 3' or 5' position of the pentose is a nucleotide. DNA and RNA are consisted of different types of nucleotide units called deoxyribonucleotide and ribonucleotide, respectively.
Oligonucleotide: a molecule comprised of two or more monomeric units of DNA and/or RNA, preferably more than three, and usually more than ten. An oligonucleotide longer than 13 nucleotide monomers is also called polynucleotiude. The exact size will depend on many factors, which in turn depends on the ultimate function or use of the oligonucleotide. The oligonucleotide may be generated in any manner, including chemical synthesis, DNA replication, RNA transcription, reverse transcription, or a combination thereof.
Nucleotide Analog: a purine or pyrimidine nucleotide that differs structurally from adenine (A), thymine (T), guanine (G), cytosine (C), or uracil (U), but is sufficiently similar to substitute for the normal nucleotide in a nucleic acid molecule.
Nucleic Acid Composition: a nucleic acid composition refers to an oligonucleotide or polynucleotide such as a DNA or RNA sequence, or a mixed DNA/RNA sequence, in either a single-stranded or a double-stranded molecular structure.
Gene: a nucleic acid composition whose oligonucleotide or polynucleotide sequence codes for an RNA and/or a polypeptide (protein). A gene can be either RNA or DNA. A gene may encode a non-coding RNA, such as small hairpin RNA (shRNA), microRNA (miRNA), rRNA, tRNA, snoRNA, snRNA, and their RNA precursors as well as derivatives. Alternatively, a gene may encode a protein-coding RNA essential for protein/peptide synthesis, such as messenger RNA (mRNA) and its RNA precursors as well as derivatives. In some cases, a gene may encode a protein-coding RNA that also contains at least a microRNA or shRNA sequence.
Primary RNA Transcript: an RNA sequence that is directly transcribed from a gene without any RNA processing or modification.
Precursor messenger RNA (pre-mRNA): primary RNA transcripts of a protein-coding gene, which are produced by eukaryotic type-II RNA polymerase (Roΐ-P) machineries in
eukaryotes through an intracellular mechanism termed transcription. A pre-mRNA sequence contains a 5’ -untranslated region (UTR), a 3’-UTR, exons and introns.
Intron: a part or parts of a gene transcript sequence encoding non-protein-reading frames, such as in-frame intron, 5’ -UTR and 3’ -UTR. Exon: a part or parts of a gene transcript sequence encoding protein-reading frames
(cDNA), such as cDNA for cellular genes, growth factors, insulin, antibodies and their analogs/homologs as well as derivatives.
Messenger RNA (mRNA): assembly of pre-mRNA exons, which is formed after intron removal by intracellular RNA splicing machineries (e.g. spliceosomes) and served as a protein-coding RNA for peptide/protein synthesis. The peptides/proteins encoded by mRNAs include, but not limited, enzymes, growth factors, insulin, antibodies and their analogs/homologs as well as derivatives.
Complementary DNA (cDNA): a single-stranded or double-stranded DNA that contains a sequence complementary to an mRNA sequence and does not contain any intronic sequence.
Sense: a nucleic acid molecule in the same sequence order and composition as the homologous mRNA. The sense conformation is indicated with a “+”, “s” or “sense” symbol.
Antisense: a nucleic acid molecule complementary to the respective mRNA molecule. The antisense conformation is indicated as a symbol or with an "a" or “antisense” in front of the DNA or RNA, e.g., "aDNA" or "aRNA".
Base Pair (bp): a partnership of adenine (A) with thymine (T), or of cytosine (C) with guanine (G) in a double stranded DNA molecule. In RNA, uracil (U) is substituted for thymine. Generally the partnership is achieved through hydrogen bonding. For example, a
sense nucleotide sequence "5’-A-T-C-G-U-3’" can form complete base pairing with its antisense sequence "5’-A-C-G-A-T-3’".
5 ’-end: a terminus lacking a nucleotide at the 5’ position of successive nucleotides in which the 5’-hydroxyl group of one nucleotide is joined to the 3’-hydroyl group of the next nucleotide by a phosphodiester linkage. Other groups, such as one or more phosphates, may be present on the terminus.
3 ’-end: a terminus lacking a nucleotide at the 3’ position of successive nucleotides in which the 5’-hydroxyl group of one nucleotide is joined to the 3’-hydroyl group of the next nucleotide by a phosphodiester linkage. Other groups, most often a hydroxyl group, may be present on the terminus.
Template: a nucleic acid molecule being copied by a nucleic acid polymerase. A template can be single-stranded, double-stranded or partially double-stranded, RNA or DNA, depending on the polymerase. The synthesized copy is complementary to the template, or to at least one strand of a double-stranded or partially double-stranded template. Both RNA and DNA are synthesized in the 5' to 3' direction. The two strands of a nucleic acid duplex are always aligned so that the 5' ends of the two strands are at opposite ends of the duplex (and, by necessity, so then are the 3' ends).
Nucleic Acid Template: a double-stranded DNA molecule, double-stranded RNA molecule, hybrid molecules such as DNA-RNA or RNA-DNA hybrid, or single-stranded DNA or RNA molecule.
Conserved: a nucleotide sequence is conserved with respect to a pre-selected
(referenced) sequence if it non-randomly hybridizes to an exact complement of the pre selected sequence.
Homologous or Homology: a term indicating the similarity between a polynucleotide and a gene or mRNA sequence. A nucleic acid sequence may be partially or completely
homologous to a particular gene or mRNA sequence, for example. Homology may be expressed as a percentage determined by the number of similar nucleotides over the total number of nucleotides.
Complementary or Complementarity or Complementation: a term used in reference to matched base pairing between two polynucleotides (i.e. sequences of an mRNA and a cDNA) related by the aforementioned “base pair (bp)” rules. For example, the sequence "5’-A-G-T- 3’" is complementary to not only the sequence "5’-A-C-T-3’" but also to "5’-A-C-U-3’". Complementation can be between two DNA strands, a DNA and an RNA strand, or between two RNA strands. Complementarity may be "partial" or "complete" or "total". Partial complementarity or complementation occurs when only some of the nucleic acid bases are matched according to the base pairing rules. Complete or total complementarity or complementation occurs when the bases are completely or perfectly matched between the nucleic acid strands. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as in detection methods that depend on binding between nucleic acids. Percent complementarity or complementation refers to the number of mismatch bases over the total bases in one strand of the nucleic acid. Thus, a 50% complementation means that half of the bases were mismatched and half were matched. Two strands of nucleic acid can be complementary even though the two strands differ in the number of bases. In this situation, the complementation occurs between the portion of the longer strand corresponding to the bases on that strand that pair with the bases on the shorter strand.
Complementary Bases: nucleotides that normally pair up when DNA or RNA adopts a double stranded configuration.
Complementary Nucleotide Sequence: a sequence of nucleotides in a single-stranded molecule of DNA or RNA that is sufficiently complementary to that on another single strand to specifically hybridize between the two strands with consequent hydrogen bonding.
Hybridize and Hybridization: the formation of duplexes between nucleotide sequences which are sufficiently complementary to form complexes via base pairing. Where a primer (or splice template) "hybridizes" with target (template), such complexes (or hybrids) are sufficiently stable to serve the priming function required by a DNA polymerase to initiate DNA synthesis. There is a specific, i.e. non-random, interaction between two complementary polynucleotides that can be competitively inhibited. Posttranscriptional Gene Silencing: a targeted gene knockout or knockdown effect at the level of mRNA degradation or translational suppression, which is usually triggered by either foreign/viral DNA or RNA transgenes or small inhibitory RNAs.
RNA Interference (RNAi): a posttranscriptional gene silencing mechanism in eukaryotes, which can be triggered by small inhibitory RNA molecules such as microRNA (miRNA), small hairpin RNA (shRNA) and small interfering RNA (siRNA). These small RNA molecules usually function as gene silencers, interfering with expression of intracellular genes containing either completely or partially complementarity to the small RNAs.
Gene Silencing Effect: a cell response after a gene function is suppressed, consisting but not limited of cell cycle attenuation, G0/G1 -checkpoint arrest, tumor suppression, anti- tumorigenecity, cancer cell apoptosis, and a combination thereof.
Non-coding RNA: an RNA transcript that cannot be used to synthesize peptides or proteins through intracellular translation machineries. Non-coding RNA includes long and short regulatory RNA molecules such as microRNA (miRNA), small hairpin RNA (shRNA), small interfering RNA (siRNA) and double strand RNA (dsRNA). These regulatory RNA
molecules usually function as gene silencers, interfering with expression of intracellular genes containing either completely or partially complementarity to the non-coding RNAs.
MicroRNA (miRNA): single-stranded RNAs capable of binding to targeted gene transcripts that have partial complementarity to the miRNA. MiRNA is usually about 17-27 oligonucleotides in length and is able to either directly degrade its intracellular mRNA target(s) or suppress the protein translation of its targeted mRNA, depending on the complementarity between the miRNA and its target mRNA. Natural miRNAs are found in almost all eukaryotes, functioning as a defense against viral infections and allowing regulation of gene expression during development of plants and animals.
Precursor MicroRNA (Pre-miRNA): hairpin-like single-stranded RNAs containing stem-arm and stem-loop regions for interacting with intracellular RNaselll endoribonucleases to produce one or multiple microRNAs (miRNAs) capable of silencing a targeted gene or genes complementary to the microRNA sequence(s). The stem-arm of a pre-miRNA can form either a perfectly (100%) or a partially (mis-matched) hybrid duplexes, while the stem- loop connects one end of the stem-arm duplex to form a circle or hairpin-loop conformation. In the present invention, however, precursor of microRNA may also includes pri-miRNA.
Small interfering RNA (siRNA): short double-stranded RNAs sized about 18-27 perfectly base-paired ribonucleotide duplexes and capable of degrading target gene transcripts with almost perfect complementarity.
Small or short hairpin RNA (shRNA): single-stranded RNAs that contain a pair of partially or completely matched stem-arm nucleotide sequences divided by an unmatched loop or bubble oligonucleotide to form a hairpin-like structure. Many natural miRNAs are derived from small hairpin-like RNA precursors, namely precursor microRNA (pre-miRNA).
Vector: a recombinant nucleic acid composition such as recombinant DNA (rDNA) capable of movement and residence in different genetic environments. Generally, another
nucleic acid is operatively linked therein. The vector can be capable of autonomous replication in a cell in which case the vector and the attached segment is replicated. One type of preferred vector is an episome, i.e., a nucleic acid molecule capable of extrachromosomal replication. Preferred vectors are those capable of autonomous replication and expression of nucleic acids. Vectors capable of directing the expression of genes encoding for one or more polypeptides and/or non-coding RNAs are referred to herein as “expression vectors” or “expression-competent vectors”. Particularly important vectors allow cloning of cDNA from mRNAs produced using a reverse transcriptase. A vector may contain components consisting of a viral or a type-II RNA polymerase (Pol-II or pol-2) promoter, or both, a Kozak consensus translation initiation site, polyadenylation signals, a plurality of restriction/cloning sites, a pUC origin of replication, a SV40 early promoter for expressing at least an antibiotic resistance gene in replication-competent prokaryotic cells, an optional SV40 origin for replication in mammalian cells, and/or a tetracycline responsive element. The structure of a vector can be a linear or circular form of single- or double- stranded DNA selected form the group consisting of plasmid, viral vector, transposon, retrotransposon, DNA transgene, jumping gene, and a combination thereof.
Promoter: a nucleic acid to which a polymerase molecule recognizes, perhaps binds to, and initiates RNA transcription. For the purposes of the instant invention, a promoter can be a known polymerase binding site, an enhancer and the like, any sequence that can initiate synthesis of RNA transcripts by a desired polymerase.
Restriction Site: a DNA motif for restriction enzyme cleavage including but not limited Audi, Accl, AflII/III, Agel, Apal/LI, Asel, Asp718I, BamHI, Bbel, BclI/II, Bglll, Bsml, Bspl20I, BspHI/LUl 11/1201, BsrI/BI/GI, BssHII/SI, BstBI/Ul/XI, Clal, Csp6I, Dpnl, Dral/II, Eagl, Eel 13611, EcoRI/RIE47III/RV, Ehel, Fspl, Haelll, Hhal, HinPI, Hindlll, Hinfl, HpaEII, Kasl, Kpnl, Maell/III, Mfel, Mlul, Mscl, Msel, Nael, Narl, Ncol, Ndel, NgoMI, Notl, Nrul,
Ns/I, Pmll, PpulOI, Pstl, PvuI/II, Rsal, SacI/II, Sail, Sau3AI, Smal, SnaBI, Sphl, Sspl, Stul, Tail, Taql, Xbal, Xhol , Xmal cleavage site.
Cistron: a sequence of nucleotides in a DNA molecule coding for an amino acid residue sequence and including upstream and downstream DNA expression control elements.
RNA Processing: a cellular mechanism responsible for RNA maturation, modification and degradation, including RNA splicing, intron excision, exosome digestion, nonsense- mediated decay (NMD), RNA editing, RNA processing, 5’ -capping, 3’-poly(A) tailing, and a combination thereof.
Gene Delivery: a genetic engineering method selected from the group consisting of polysomal transfection, liposomal transfection, chemical (nanoparticle) transfection, electroporation, viral infection, DNA recombination, transposon insertion, jumping gene insertion, microinjection, gene-gun penetration, and a combination thereof.
Genetic Engineering: a DNA recombination method selected from the group consisting of DNA restriction and ligation, homologous recombination, transgene incorporation, transposon insertion, jumping gene integration, retroviral infection, and a combination thereof.
Tumor Suppression: a cellular anti-tumor and anti-cancer mechanism consisting but not limited of cell cycle attenuation, G0/G1 -checkpoint arrest, tumor suppression, anti- turn origenecity, cancer cell apoptosis, and a combination thereof.
Targeted Cell: a single or a plurality of human cells selected from the group consisting of a somatic cell, a tissue cell, a stem cell, a germ-line cell, a tumor cell, a cancer cell, a virus- infected cell, and a combination thereof.
Cancerous Tissue: a neoplastic tissue derived from the group consisting of skin cancer, prostate cancer, breast cancer, liver cancer, lung cancer, brain tumor/cancer, lymphoma, leukemia and a combination thereof.
Antibody: a peptide or protein molecule having a pre-selected conserved domain structure coding for a receptor capable of binding a pre-selected ligand.
Pharmaceutical and/or therapeutic Application: a biomedical utilization and/or apparatus useful for stem cell generation, stem cell research and/or therapy development, cancer therapy, disease treatment, wound healing and tissue regeneration treatment, high- yield production of drug and/or food supplies, and a combination thereof.
Prokaryote or Prokaryotic Cell: an one-cell organism that lacks a distinct membrane- bound nucleus and has its genetic materials in the form of a continuous strand of DNA, such as bacteria.
Eukaryote or Eukaryotic Cell: an one-cell or multiple-cell organism whose cells contain a nucleus and other structures (organelles) enclosed within membranes, such as yeast, plant and animal cells.
Transcription Inducer: a chemical agent that can induce and/or enhance eukaryotic RNA and/or gene transcription from a eukaryotic pol-2 or pol-2 equivalent promoter in prokaryotic cells. For example, a transcription inducer contains, but not limited, a chemical structure similar to 3 -morpholinopropane-1 -sulfonic acid (MOPS), ethanol and/or glycerin, as well as their functional analogs, such as mannitol, 2-(N-morpholino)ethanesulfonic acid (MES) and 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES), or a mixture thereof.
B. Compositions and Applications
A novel RNA composition and its production method for use in induced pluripotent stem cell (iPSC) generation, comprising: at least a miR-302 precursor RNA (pre-miR-302) construct and at least an RNA- dependent RNA polymerase (RdRp) mRNA, wherein the pre-miR-302 construct contains at
least a 5’ -end RdRp binding site or at least a 3’ -end RdRp binding site, or both, and wherein the RdRp mRNA is isolated and/or modified from RNA virus, preferably from coronavirus or hepatitis C virus.
Structurally, the 5’ -end RdRp binding site contains at least a sequence of either 5’- AU(G/C)(U/-)G(A/U)-3 ’ (5’-AUSUGW-3’; SEQ.ID.NO.l) or 5’-U(C/-
)(U/A)C(U/C)(U/A)A-3 ’ (5’-UCWCYWA-3’; SEQ.ID.NO.2), or both. For instance, the 5’- end RdRp binding site is preferably selected from at least an RNA sequence containing 5’- AUCUGU-3’ (SEQ.ID.NO.3), 5’-UCUCUAA-3’ (SEQ.ID.NO.4), 5’-UCUCCUA-3’ (SEQ.ID.NO.5), and/or 5’-UUCAA-3’ (SEQ.ID.NO.6), or a combination thereof. On the other hand, the 3’ -end RdRp binding site contains at least a sequence of either 5’-(U/A)C(A/- )(C/G)AU-3’ (5’-WCASAU-3’; SEQ.ID.N0.7) or 5 -U( A/U)( A/G)G( A/U)(G/-) A-3 (5’- UWRGWR-3’; SEQ.ID.NO.8), or both. For example, the 3’-end RdRp binding site is preferably selected from at least an RNA sequence containing 5’-ACAGAU-3’ (SEQ.ID.NO.9), 5 ’ -UUAGAGA-3 ’ (SEQ.ID.NO.10), 5’-UAGGAGA-3’ (SEQ.ID.NO.i l), and/or 5’-UUGAA-3’ (SEQ.ID.NO.12), or a combination thereof.
In addition, the pre-miR-302 construct contains at least a hairpin-like miR-302 precursor sequence preferably selected from 5’-CCUUUGCUUU AACAUGGGGG UACCUGCUGU GUGAAACAAA AGUAAGUGCU UCCAUGUUUC AGUGGAGG-3’ (SEQ.ID.NO.13), 5’-GCUCCCUUCA ACUUUAACAU GGAAGUGCUU UCUGUGACUU UAAAAGUAAG UGCUUCCAUG UUUUAGUAGG AGU-3’ (SEQ.ID.NO.14), 5’- CCACCACUUA AACGUGGAUG UACUUGCUUU GAAACUAAAG AAGUAAGUGC UUCCAUGUUU UGGUGAUGG-3 ’ (SEQ.ID.NO.15), and/or 5’-CCUCUACUUU AACAUGGAGG CACUUGCUGU GACAUGACAA AAAUAAGUGC UUCCAUGUUU GAGUGUGG-3’ (SEQ.ID.NO.16), or a combination thereof. Between two individual miR- 302 precursor sequences, there may further contain a 50~500-nucleotide spacer sequence for
preventing hairpin tangle formation. Conceivably, these miR-302 precursor sequences can be replaced by using miR-302-mimic siRNA and/or shRNA sequences for eliciting the same cell reprogramming functionality. Also, the uridine (U) content of these RNA sequences can be further replcaed by pseudouridine and/or other modified nucleotides to increase the stability of the pre-miR-302 construct.
To overcome the low efficiency problem of hairpin-like RNA production, the pre-miR- 302 and RdRp mRNA are preferably produced using a novel PCR-IVT methodology with an RNA polymerase-helicase mixture activity and an improved buffer system. Also, for increasing the efficiency of intracelluar delivery, the design pre-miR-302 and RdRp mRNA mixture composition can be further mixed, conjugated, encapsulated and/or formulated with at least a delivery agent selected from glycylglycerins, liposomes, nanoparticles, liposomal nanoparticles (LNP), conjugating molecules, infusion chemicals, gene gun materials, transposons, electroporation agents, and a combination thereof. BRIEF DESCRIPTION OF THE DRAWINGS:
Referring particularly to the drawings for the purpose of illustration only and not limitation, there is illustrated:
FIG. 1 depicts the step-by-step procedure of the PCR-IVT methodology. For RNA production, a part or whole procedure of this PCR-IVT method can be adopted for either single or multiple cycle amplification of desired RNA products.
FIG. 2 depicts one of the preferred designs of the miR-302 precursor RNA (pre-miR- 302) construct. At least an RNA-dependent RNA polymerase (RdRp)-binding site or more can be placed in either 5’ -end or 3’ -end region, or both, of the pre-miR-302 construct.
FIG. 3 shows markedly increased expressions of miR-302s {i.e. top to bottom: b, c, d, a) and RdRp mRNA in reprogrammed cells after co-transfection of both pre-miR-302 and RdRp mRNA (right) compared to that of transfection of only pre-miR-302 (middle), using Northern blot analysis. FIG. 4 shows elevated expression of standard embryonic stem cell (ESC) markers such as Oct3/4, Sox2 and Nanog found in reprogrammed cells three days after co-transfection of pre-miR-302 and RdRp mRNA, using Western blot analysis.
FIG. 5 shows iPSC-derived embryoid body formation after co-transfection of pre- miR-302 and RdRp mRNA. FIG. 6 shows global genomic DNA demethylation observed in the reprogrammed cells, similar to the status of human ESC genome.
FIG. 7 shows >92% high similarity of genome-wide gene expression patterns compared to those of human ESC WA01 (HI) and WA09 (H9) cell lines, using microarray analysis. FIG. 8 shows iPSC-derived teratoma formation containing tissues derived from all three embryonic germ layers (ectoderm, mesoderm and definitive endoderm), using immunohisto-chemical staining with respective tissue cell markers.
EXAMPLES: 1. Human Cell Isolation and Cultivation
Starting tissue cells can be obtained from either enzymatically dissociated skin cells using Aasen’s protocol {Nat. Protocols 5, 371-382, 2010) or simply from the buffy coat fraction of heparin-treated peripheral blood cells. The isolated tissue samples must be kept
fresh and used immediately by mixing with 4 mg/mL collagenase I and 0.25% TrypLE for 15-45 min, depending on cell density, and rinsed by HBSS containing trypsin inhibitor two times and then transferred to a new sterilized microtube containing 0.3 mL of feeder-free SFM culture medium (IrvineScientific, CA). After that, cells were further dissociated by shaking in a microtube incubator for 1 min at 37°C and then transferred the whole 0.3 mL cell suspension to a 35-mm Matrigel-coated culture dish containing 1 mL of feeder-free SFM culture medium supplemented with formulated pre-miR-302+RdRp mRNA mixture, LIF, and bFGF/FGF2, or other optional defined factors. The used concentrations of pre-miR- 302+RdRp mRNA mixture, LIF, bFGF/FGF2, and other optional defined factors is ranged from 0.1 to 500 microgram (pg)/mL, respectively, in the cell culture medium. The cell culture medium and all of the supplements must be refreshed every 2~3 days and the cells are passaged at about 50%~60% confluence by exposing the cells to trypsin/EDTA for 1 min and then rinsing two times in HBSS containing trypsin inhibitor. For ASC expansion, the cells were replated at 1:5-1:500 dilution in fresh feeder-free MSC Expansion SFM culture medium supplemented with formulated pre-miR-302+RdRp mRNA mixture, LIF, bFGF/FGF2, and/or other optional defined factors. For culturing keratinocytes, cells are isolated from skin tissues and cultivated in EpiLife serum-free cell culture medium supplemented with human keratinocyte growth supplements (HKGS, Invitrogen, Carlsbad, CA) in the presence of proper antibiotics at 37°C under 5% CO2. Culture cells are passaged at 50%-60% confluency by exposing cells to trypsin/EDTA solution for 1 min and rinsing once with phenol red-free DMEM medium (Invitrogen), and the detached cells are replated at 1:10 dilution in fresh EpiLife medium with HKGS supplements. Human cancer and normal cell lines A549, MCF7, PC3, HepG2, Colo-829 and BEAS-2B were obtained either from the American Type Culture Collection (ATCC, Rockville, MD) or our collaborators and then maintained according to manufacturer’s or provider’s suggestions. After reprogramming, the resulting
iPS cells (iPSCs) were cultivated and maintained following either Lin’s feeder-free or Takahashi’s feeder-based iPSC culture protocols (Lin et al., RNA 14:2115-2124, 2008; Lin et al., Nucleic Acids Res. 39:1054-1065, 2011; Takahashi K and Yamanaka S, Cell 126:663- 676, 2006). 2. In-Vitro RNA Transfection
For RNA transfection, 0.5-500 pg of isolated pre-miR-302 and RdRp mRNA mixture (ratio ranged from about 20:1 to 1:20) is dissolved in 0.5 ml of fresh cell culture medium and mixed with 1-50 mΐ of In-VivoJetPEI or other similar transfection reagents. After 10-30 min incubation, the mixture is then added into a cell culture containing 50%-60% confluency of the cultivated cells. The medium is reflashed every 12 to 48 hours, depending on cell types. This transfection procedure may be performed repeatedly to increase transfection efficiency. The transfection results are further analyzed by various detection methods and shown in FIG. 3 to FIG. 8, respectively.
3. DNA Demethylation Assay Genomic DNAs were isolated from about two million cells with a Roche DNA isolation kit (Sigma-Aldrich, MO, USA). About 2 microgram (pg) of the isolated genomic DNAs was digested with a CCGG-cutting restriction enzyme, Hpall , and then assessed with 1% agarose gel electrophoresis to determine genome-wide demethylation (FIG. 4).
4. Genome-Wide Microarrav Analysis of Global Cellular Gene Expression Patterns Human genome GeneChip arrays (Affymetrix, CA) were used to detect the expression patterns of genome-wide 47,000 human gene transcripts in iPS cells, as shown in FIG. 7. Each sample was tested in triplicate and the same experiment was repeated for four times. Total RNAs from each tested sample were isolated using RNeasy spin columns (Qiagen, MD). To prepare labeled probes for microarray hybridization, the extracted total RNAs (2
pg) were converted into cDNAs, using a T7 promoter-containing oligo(dT)24 primer and Superscript double-stranded cDNA synthesis kit (ThermoFisher Scientific, MA), following manufacturer’s protocols. The resulting cDNAs were purified by phenol-chloroform extractions, precipitated with ethanol, and resuspended at a concentration of 0.5 pg/mΐ in diethyl pyrocarbonate (DEPC)-treated ddFFO. Then, in-vitro transcription was performed, containing 1 pg of the dsDNAs, 7.5 mM unlabeled ATP and GTP, 5 mM unlabeled UTP and CTP, and 2 mM biotin-labeled CTP and UTP (biotin- 11-CTP, biotin- 16-UTP, Enzo Diagnostics), and 20 U of T7 RNA polymerase. Reactions were carried out for 4 hours at 37°C, and the resulting cRNAs were purified by RNeasy spin columns (Qiagen). A part of the cRNA sample was separated on a 1% agarose gel to check the size range, and then 10 pg of the cRNAs were fragmented randomly to an average size of 50 bases by heating at 94°C for 35 min in 40 mM Tris-acetate, pH 8.0, 100 mM KOAc/30 mM MgOAc. Hybridizations were completed in 200 pi of AFFY buffer (Affymetrix, CA) at 40°C for 16 hours with constant mixing. After hybridization, arrays were rinsed three times with 200 pi of 6x SSPE-T buffer (lx 0.25 M sodium chloride/15 mM sodium phosphate, pH 7.6/1 mM EDTA/0.005% Triton) and then washed with 200 pi of 6x SSPE-T for 1 hour at 50°C. The arrays were further rinsed twice with 0.5X SSPE-T and washed with 0.5x SSPE-T at 50°C for 15 min. Then, staining assays were done with 2 pg/ml streptavidin-phycoerythrin (Invitrogen) and 1 mg/ml acetylated BSA (Sigma-Aldrich) in 6x SSPE-T (pH 7.6). The arrays were read at 7.5 pm with a confocal scanner (Molecular Dynamics).
To identify the background variations, we duplicated the microarray tests using the same sample and selected two hundred genes, which were slightly presented in one side of the tests, for further comparison. The sample signals were normalized using the total average difference between perfectly matched probes and mismatched probes. Then, alterations of overall genome-wide gene expression patterns were analyzed using Affymetrix Microarray
Suite version 5.0, Expression Console™ (Affymetrix) and Genesprings (Silicon Genetics) softwares. Changes in gene expression rates more than 1-fold were considered as positive differential genes. In gene clustering assays, a plug-in program Genetrix (Epicenter Software) was used in conjunction with the Affymetrix softwares. Signals of the sample were normalized with the internal house-keeping control average in each microarray. After normalization, as signal intensity increased from level 1 to level 65,535, the corresponding color changed from green to black, and to red. The level above 23,000 was considered to be a positive call in that a Northern blotting assay could positively detect.
5. Teratoma Formation and Guided iPSC Differentiation Xenograft transplantation of iPS-derived embryoid bodies into the uterus or peritoneal cavity of a 6-week-old female pseudopregnant immunocompromised SCID-beige mouse formed teratoma-like cysts, containing tissues derived from all three embryonic germ layers (ectoderm, mesoderm and definitive endoderm) (FIG. 8). The use of immunocompromised nude mice was to provide an in vivo environment mimicking transplantation therapy. The pseudopregnant mice were made by intraperitoneally injection of 1 IU human menopausal gonadotrophin (HMG) for two days and then human chorionic gonadotrophin (hCG) for one more day. For In vitro guidance of stem cell differentiation into the germ line lineage, iPS cells were maintained on polyornithine/ laminin-coated dishes in DMEM/F12 (1:1; high glucose) medium supplemented with charcoal-stripped 10% FBS, 4 mM L-glutamine, 1 mM sodium pyruvate, 5 ng/ml activin and 50 ng/ml dihydrotestosterone (DHT) for 12 hours, at 37°C under 5% CO2. Then the cells were trypsinized, washed with lx PBS, and collected in four aliquots of chilled Matrigel (100 mΐ each) and one aliquots of 100 mΐ lx PBS. Immediately after that, we transplanted the cells into the hind limb muscle, peritoneum, uterus, subcutaneous neck skin (with Matrigel) and tail vein (with PBS) of 6-week-old
immunocompromised SCID-beige nude mice. The mice were anesthetized with diethyl ether during experimental processing.
6. Immunostaining Assay
Cell/Tissue samples are fixed in 100% methanol for 30 min at 4°C and then 4% paraformaldehyde (in lx PBS, pH 7.4) for 10 min at 20°C. After that, the samples are incubated in lx PBS containing 0.1%~0.25% Triton X-100 for 10 min and then washed in lx PBS three times for 5 min. For immunostaining, primary antibodies were purchased from Invitrogen (CA, USA) and Sigma-Aldrich (MO, USA), respectively. Dye-labeled goat anti rabbit or horse anti-mouse antibody are used as the secondary antibody (Invitrogen, CA, USA). Results are examined and analyzed at lOOx or 200x magnification under a fluorescent 80i microscopic quantitation system with a Metamorph imaging program (Nikon).
7. Novel PCR-IVT Protocol
Reverse transcription (RT) of desired mRNA is performed by adding about 0.01 ng~10 microgram (pg) of isolated mRNA into a 20-50 pL RT reaction (Superscript PI cDNA RT kit, ThermoFisher Scientific, MA, USA), following the manufacturer’s suggestions. Depending on the mRNA amount, the RT reaction mixture contains the mRNA, about 0.01-20 nmole RT primer, a proper amount of dNTPs and reverse transcriptase in lx RT buffer. Then, the RT reaction is incubated at 46~65°C for 1-3 hours (hr), depending on the structure and length of the desired mRNA, so as to make at least a complementary DNA (cDNA) template for the next step of PCR. For cloning of viral RdRp cDNA, we design and use an RT -reverse primer 5’-GACAACAGGT GCGCTCAGGT COT S’ (SEQ.ID.NO.17) to perform RT of coronaviral COVID-19 mRNA into cDNA.
Next, polymerase chain reaction (PCR) is performed by adding about 0.01 pg~10 pg of the RT-derived cDNAs into a 20-50 pL PCR preparation mixture (High-Fidelity PCR kit,
ThermoFisher Scientific, MA, USA), following the manufacturer’s suggestions. Then, the PCR mixture is first incubated in five to twenty (5~20) cycles of denaturation at 94°C for 1 mim, annealing at 30~55°C for 30 sec~l min, and then extension at 72°C for 1~3 min, depending on the structure and length of the desired DNA and primers. After that, another ten to twenty (10-20) cycles of PCR are performed with a series of sequential steps of denaturation at 94°C for 1 mim, annealing at 50~55°C for 30 sec, and then extension at 72°C for 1-3 min, depending on the structure and length of the resulting PCR products. Finally, the resulting PCR products are used as templates for IVT. For IVT template preparation, we design and use a specific pair of PCR primers for amplifying RNA promoter-containing RdRp cDNA templates from coronaviral mRNA, including SEQ.ID.NO.17 and 5’- GATATCTAAT ACGACTCACT AT AGGGAGAG GTATGGTACT TGGTAGTT-3’ (SEQ.ID.NO.18). Later, a 5’-cap nucleotide may be further incorporated in the resulting mRNA products during or after IVT. On the other hand, we also design and use another pair of PCR primers for amplifying RNA promoter-containing miR-302 familial cluster cDNA templates from isolated human cell genome DNAs, including 5’-GATATCTAAT ACGACTCACT AT AGGG AG AT CTGTGGGAAC TAGTTCAGGA AGGTAA-3’ (SEQ.ID.NO.19) and 5’-GTTCTCCTAA GCCTGTAGCC AAGAACTGCA CA-3’ (SEQ.ID.NO.20). In the designed primers, various RNA promoter sequences can be used, such as T7, T3 and/or SP6 promoter, and at least a RdRp initiation/binding site has been incorporated in the 5’-forward and 3’-reverse primer sequences, respectively. Also, the resulting miR-302 familial cluster template contains the cDNA sequences of at least one pre- miR-302a (SEQ.ID.NO.13), pre-miR-302b (SEQ.ID.NO.14), pre-miR-302c (SEQ.ID.NO.15), and/or pre-miR-302d (SEQ.ID.NO.16). Multiple same or different pre-miR-302 sequences can be repeatedly placed in the miR-302 familial cluster up to 9 hairpin-structured sequences.
For mRNA production, since a promoter-primer has been incorporated into the resulting PCR products, an improved IVT reaction can be performed to amplify desired mRNA sequences, using the PCR products as templates. The IVT reaction mixture contains 0.01 ng~10 pg of the PCR product, 0.1-10 U of isolated coronaviral helicase (i.e. from COVID-19), a proper amount of NTPs and RNA polymerase (i.e. T7, T3, or SP6) in lx transcription buffer. The contents of lx transcription buffer may be adjusted according to the used RNA polymerase, following the manufacturer’s suggestions. Additionally, the lx transcription buffer may further conatin 0.001-10 mM of betaine (trimethylglycine, TMG), dimethylsulfoxide (DMSO), and/or 3-(N-morpholino)propane sulfonic acid (MOPS), and/or a combination thereof, which facilitates the denaturation of highly structured RNA/DNA sequences, such as hairpins and stem-loop structures. Then, the IVT reaction is incubated at 37°C for 1-6 hr, depending on the stability and activity of the used RNA polymerase(s). In this improved novel IVT reaction, at least an additional helicase enzyme is added in order to facilitate the unwinding of RNA/DNA secondary structures, such as hairpin-like stem-loop structures, so as to overcome the low efficiency problem of hairpin-like RNA production in vitro. Notably, the helicase enyme can unwind the secondary structures in both DNA and RNA strands.
8. RNA Purification and Northern Blot Analysis
Desired mRNAs (10 pg) are isolated with a mi W ana™ RNA isolation kit (Ambion, Austin, TX), following the manufacturer’s protocol, and then further purified by using either 15% TBE-urea polyacrylamide gel or 3.5% low melting point agarose gel electrophoresis. For Northern blot analysis, the gel -fractionated mRNAs are electroblotted onto a nylon membrane. Detection of the mRNA and its IVT template (the PCR product) is performed with a labeled [LNAJ-DNA probe complementary to a desired target sequence of the mRNA. The probe is further purified by high-performance liquid chromatography (HPLC) and tail-
labeled with terminal transferase (20 units) for 20 min in the presence of either a dye-labeled nucleotide analog or [32P]-dATP (> 3000 Ci/mM, Amersham International, Arlington Heights, IL).
9. Protein Extraction and Western Blot Analysis Cells (106) are lysed with a CelLytic-M lysis/extraction reagent (Sigma) supplemented with protease inhibitors, Leupeptin, TLCK, TAME and PMSF, following the manufacturer’s suggestion. Lysates are centrifuged at 12,000 rpm for 20 min at 4°C and the supernatant is recovered. Protein concentrations are measured using an improved SOFTmax protein assay package on an E-max microplate reader (Molecular Devices, CA). Each 30 pg of cell lysate are added to SDS-PAGE sample buffer under reducing (+50 mM DTT) and non-reducing (no DTT) conditions, and boiled for 3 min before loading onto a 6~8% polyacylamide gel. Proteins are resolved by SDS-polyacrylamide gel electrophoresis (PAGE), electroblotted onto a nitrocellulose membrane and incubated in Odyssey blocking reagent (Li-Cor Biosciences, Lincoln, NB) for 2 hr at room temperature. Then, a primary antibody is applied to the reagent and incubated the mixture at 4°C. After overnight incubation, the membrane is rinsed three times with TBS-T and then exposed to goat anti-mouse IgG conjugated secondary antibody to Alexa Fluor 680 reactive dye (1:2,000; Invitrogen-Molecular Probes), for 1 hr at the room temperature. After three additional TBS-T rinses, fluorescent scanning of the immunoblot and image analysis are conducted using Li-Cor Odyssey Infrared Imager and Odyssey Software v.10 (Li-Cor).
10. In Vivo Transfection Assay
Isolated pre-miR-302 and RdRp mRNA mixture is mixed well with a proper amount of delivery agent, such as an In-VivoJetPEI transfection reagent, following the manufacturer’s protocol, and then injected into blood veins or muscles of an animal, depending the purpose
of applications. The delivery agent is used for mixing, conjugating, encapsulating or formulating the isolated pre-miR-302 and RdRp mRNA mixture, so as to not only protect the RNA contents from degradation but also facilitate the delivery of the isolated pre-miR-302 and RdRp mRNA mixture into specific target cells of interest in vitro, ex vivo and/or in vivo. 11. Statistic Analysis
All data were shown as averages and standard deviations (SD). Mean of each test group was calculated by AVERAGE of Microsoft Excel. SD was performed by STDEV. Statistical analysis of data was performed by One-Way ANOVA. Tukey and Dunnetfs t post hoc test were used to identify the significance of data difference in each group p <0.05 was considered significant (SPSS vl2.0, Claritas Inc).
REFERENCES:
1. European Patent No. EP2198025B1 to Shi-Lung Lin et al.
2. U.S. Patent No. 7,662,791 to Shi-Lung Lin et al. 3. U.S. Patent No. 8.080.652 to Shi-Lung Lin et al.
4. U.S. Patent No. 8,372,969 to Ying SY and Shi-Lung Lin.
5. U.S. Patent No. 8,609,831 to Shi-Lung Lin and Ying SY.
6. U.S. Patent No. 9,567,591 to Shi-Lung Lin et al.
7. U.S. Patent No. 9.637.747 to Shi-Lung Lin et al. 8. U.S. Patent No. 9.783.811 to Shi-Lung Lin et al.
9. U.S. Patent No. 8,048,999 to Yamanaka et al.
10. U.S. Patent No. 8,058,065 to Yamanaka et al.
11. U.S. Patent Application No. 15/661.346 to Shi-Lung Lin et al.
12. U.S. Patent Application No. 16/135.723 to Shi-Lung Lin et al.
13. U.S. Patent Application No. 17/489.357 to Shi-Lung Lin et al.
14. Shi-Lung Lin et al.; Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 14:2115-2124, 2008..
15. Shi-Lung Lin et al.; MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of CDK2 and CDK4/6 cell cycle pathways. Cancer Res. 70:9473-9482, 2010.
16. Shi-Lung Lin et al.; Regulation of somatic cell reprogramming through inducible mir- 302 expression. Nucleic Acids Res. 39:1054-1065, 2011.
17. Shi-Lung Lin and Ying SY; Mechanism and method for generating tumor-free iPS cells using intronic microRNA miR302 induction. Shao-Yao Ying (Ed.) MicroRNA Protocols, 2nd Ed. Chapter 23, pp 295-324, Springer Publishers press, New York, 2012.. 18. Shi-Lung Lin: Deciphering the mechanism behind induced pluripotent stem cell generation. Stem Cells 29:1645-1649, 2011.
19. Takahashi K and Yamanaka S; Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676, 2006. 0. Miyoshi et al.; Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 8:633-638, 2011. 1. Anokye-Daiiso et al.; Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 8:376-388, 2011.
22. Shi-Lung Lin and Ji H; cDNA library construction using in-vitro transcriptional amplification. Methods Mol Biol. 221 : 93 - 101 , 2003.
23. McDowell et al.; Determination of intrinsic transcription termination efficiency by RNA polymerase elongation rate. Science 266:822-825, 1994. 24. Aasen et al.; Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells. Nat. Protocols 5:371-382,
2010
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(iii) NUMBER OF SEQUENCES : 20
(2) INFORMATION FOR SEQ ID NO: 1 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 :
AUSUGW 6
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
UCWCYWA 7
(2) INFORMATION FOR SEQ ID NO: 3 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
AUCUGU 6
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
UCUCUAA 7
(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
UCUCCUA 7
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
UUCAA 5
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
WCASAU 6
(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: UWRGWR 6
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
ACAGAU 6
(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
UUAGAGA 7
(2) INFORMATION FOR SEQ ID NO: 11 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11 :
UAGGAGA 7
(2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
UUGAA 5
(2) INFORMATION FOR SEQ ID NO: 13 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 68 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: hairpin
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13 :
CCUUUGCUUU AACAUGGGGG UACCUGCUGU GUGAAACAAA AGUAAGUGCU UCCAUGUUUC AGUGGAGG 68
(2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 73 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: hairpin
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
GCUCCCUUCA ACUUUAACAU GGAAGUGCUU UCUGUGACUU UAAAAGUAAG UGCUUCC AUG UUUUAGUAGG AGU 73
(2) INFORMATION FOR SEQ ID NO: 15 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 69 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: hairpin
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15 :
CC ACC ACUUA AACGUGGAUG UACUUGCUUU GAAACUAAAG AAGUAAGUGC UUCC AUGUUU UGGUGAUGG 69
(2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 68 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: hairpin
(ii) MOLECULE TYPE: RNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
CCUCUACUUU AACAUGGAGG CACUUGCUGU GACAUGACAA AAAUAAGUGC UUCCAUGUUU GAGUGUGG 68
(2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: YES
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
GACAACAGGT GCGCTCAGGT CCT 23
(2) INFORMATION FOR SEQ ID NO: 18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 48 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
GATATCTAAT ACGACTCACT AT AGGGAGAG GTATGGTACT TGGTAGTT
48
(2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 56 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:
GATATCTAAT ACGACTCACT AT AGGGAGAT CTGTGGGAAC TAGTTCAGGA AGGTAA 56
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(A) DESCRIPTION: /desc = "synthetic"
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: YES
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: GTTCTCCTAA GCCTGTAGCC AAGAACTGCA CA 32
Claims
1. A novel RNA composition for use in induced pluripotent stem cell (iPSC) generation, comprising:
A mixture of at least a miR-302 precursor RNA (pre-miR-302) construct and at least an RNA-dependent RNA polymerase (RdRp) mRNA, wherein the pre-miR-302 construct contains at least an RdRp binding site in its 5’ -end or 3’ -end region, or both, and wherein the RdRp mRNA is isolated or modified from RNA virus.
2. The composition as defined in Claim 1, wherein the ratio of said pre-miR-302 and RdRp mRNA mixture is ranged from 20: 1 to 1 :20.
3. The composition as defined in Claim 1, wherein said 5’ -end RdRp binding site contains a sequence of either SEQ.ID.NO.1 or SEQ.ID.NO.2.
4. The composition as defined in Claim 3, wherein said 5’-end RdRp binding site is selected from a sequence containing SEQ.ID.NO.3, SEQ.ID.N0.4, SEQ.ID.NO.5, or SEQ.ID.NO.6, or a combination thereof.
5. The composition as defined in Claim 1, wherein said 3’ -end RdRp binding site contains a sequence of either SEQ.ID.NO.7 or SEQ.ID.NO.8.
6. The composition as defined in Claim 5, wherein said 3’-end RdRp binding site is selected from a sequence containing SEQ.ID.NO.9, SEQ.ID.NO.10, SEQ.ID.NO.il, or SEQ.ID.NO.12, or a combination thereof.
7. The composition as defined in Claim 1, wherein said pre-miR-302 is selected from at least a sequence containing SEQ.ID.NO.13, SEQ.ID.NO.14, SEQ.ID.NO.15, or SEQ.ID.NO.16, or a combination thereof.
8. The composition as defined in Claim 1, wherein said RdRp mRNA is isolated from RNA virus.
9. The composition as defined in Claim 1, wherein said RdRp mRNA is coronaviral or hepatitis C viral RNA-dependent RNA polymerase mRNA.
10. The composition as defined in Claim 1, wherein said pre-miR-302 is produced using a novel polymerase chain reaction-in-vitro transcription (PCR-IVT) methodology with an RNA polymerase and helicase mixture activity.
11. The composition as defined in Claim 1, wherein said RdRp mRNA is produced using a novel polymerase chain reaction-in-vitro transcription (PCR-IVT) methodology with an RNA polymerase and helicase mixture activity.
12. The composition as defined in Claim 10, wherein said helicase is an enzyme capable of unwinding both DNA and RNA secondary structures.
13. The composition as defined in Claim 10, wherein the IVT reaction of said PCR-IVT methodology is performed in an improved buffer system containing lx transcription buffer with additional 0.001-10 mM of betaine (trimethylglycine, TMG), dimethylsulfoxide (DMSO), or 3-(N-morpholino)propane sulfonic acid (MOPS), or a combination thereof.
14. The composition as defined in Claim 1, wherein said pre-miR-302 and RdRp mRNA mixture is further formulated with at least a delivery agent for facilitating intracellular transfection in vitro, ex vivo and/or in vivo.
15. The composition as defined in Claim 14, wherein said delivery agent includes glycylglycerins, liposomes, nanoparticles, liposomal nanoparticles, conjugating molecules, infusion chemicals, gene gun materials, electroporation agents, transposon, and a combination thereof.
16. The composition as defined in Claim 1, wherein said iPSCs can differentiate into various tissue cells derived from all three germ layers of ectoderm, mesoderm and endoderm.
17. The composition as defined in Claim 16, wherein said iPSC-derived tissue cells are used for developing cell-based therapies.
18. The composition as defined in Claim 1, wherein said iPSCs is used for developing stem cell-based therapies.
19. The composition as defined in Claim 1, wherein said iPSCs is used for searching and/or producing new medicine materials.
20. The composition as defined in Claim 1, wherein said pre-miR-302 and RdRp mRNA mixture is used for developing reprogramming-associated therapies and medicines.
21. The composition as defined in Claim 1, wherein said pre-miR-302 and RdRp mRNA mixture is used as an ingredient in medicines or therapies.
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163209969P | 2021-06-12 | 2021-06-12 | |
US63/209,969 | 2021-06-12 | ||
US202163210988P | 2021-06-15 | 2021-06-15 | |
US63/210,988 | 2021-06-15 | ||
US202163212657P | 2021-06-19 | 2021-06-19 | |
US63/212,657 | 2021-06-19 | ||
US202163222398P | 2021-07-15 | 2021-07-15 | |
US63/222,398 | 2021-07-15 | ||
US17/489,357 US20220396798A1 (en) | 2021-06-12 | 2021-09-29 | Novel mrna composition and production method for use in anti-viral and anti-cancer vaccines |
US17/489,357 | 2021-09-29 | ||
US202163270034P | 2021-10-20 | 2021-10-20 | |
US63/270,034 | 2021-10-20 | ||
US202163280226P | 2021-11-17 | 2021-11-17 | |
US63/280,226 | 2021-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022260719A1 true WO2022260719A1 (en) | 2022-12-15 |
Family
ID=84425225
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/013350 WO2022260718A1 (en) | 2021-06-12 | 2022-01-21 | Novel replicase cycling reaction (rcr) |
PCT/US2022/013372 WO2022260719A1 (en) | 2021-06-12 | 2022-01-21 | Novel rna composition and production method for use in ips cell generation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/013350 WO2022260718A1 (en) | 2021-06-12 | 2022-01-21 | Novel replicase cycling reaction (rcr) |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2024523006A (en) |
WO (2) | WO2022260718A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4219756A1 (en) | 2022-01-24 | 2023-08-02 | Mello Biotech Taiwan Co., Ltd. | Synthetic rna fragment and its uses for rna-dependent amplification |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130102768A1 (en) * | 2007-12-10 | 2013-04-25 | Kyoto University | Efficient method for nuclear reprogramming |
US20130210120A1 (en) * | 2011-08-12 | 2013-08-15 | Mello Biotechnology, Inc. | Inducible Gene Expression Composition for Using Eukaryotic Pol-2 Promoter-Driven Transcription in Prokaryotes and the Applications Thereof |
WO2019056090A1 (en) * | 2017-09-19 | 2019-03-28 | The Governors Of The University Of Alberta | Recombinant rna-dependent rna polymerase of rna viruses |
WO2020006036A1 (en) * | 2018-06-26 | 2020-01-02 | Massachusetts Institute Of Technology | Crispr effector system based amplification methods, systems, and diagnostics |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153510B1 (en) * | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
AU2002314782A1 (en) * | 2001-05-14 | 2002-11-25 | Henry H. Ji | Replicase cycling reaction amplification |
WO2019140116A2 (en) * | 2018-01-10 | 2019-07-18 | Rubius Therapeutics, Inc. | Amplifiable rnas for therapeutic cell systems |
-
2022
- 2022-01-21 WO PCT/US2022/013350 patent/WO2022260718A1/en active Application Filing
- 2022-01-21 WO PCT/US2022/013372 patent/WO2022260719A1/en active Application Filing
- 2022-01-21 JP JP2023575381A patent/JP2024523006A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130102768A1 (en) * | 2007-12-10 | 2013-04-25 | Kyoto University | Efficient method for nuclear reprogramming |
US20130210120A1 (en) * | 2011-08-12 | 2013-08-15 | Mello Biotechnology, Inc. | Inducible Gene Expression Composition for Using Eukaryotic Pol-2 Promoter-Driven Transcription in Prokaryotes and the Applications Thereof |
WO2019056090A1 (en) * | 2017-09-19 | 2019-03-28 | The Governors Of The University Of Alberta | Recombinant rna-dependent rna polymerase of rna viruses |
WO2020006036A1 (en) * | 2018-06-26 | 2020-01-02 | Massachusetts Institute Of Technology | Crispr effector system based amplification methods, systems, and diagnostics |
Non-Patent Citations (1)
Title |
---|
MEIER E, HARMISON G G, KEENE J D, SCHUBERT M: "Sites of copy choice replication involved in generation of vesicular stomatitis virus defective-interfering particle RNAs", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 51, no. 2, 1 August 1984 (1984-08-01), US , pages 515 - 521, XP093016544, ISSN: 0022-538X, DOI: 10.1128/jvi.51.2.515-521.1984 * |
Also Published As
Publication number | Publication date |
---|---|
WO2022260718A1 (en) | 2022-12-15 |
JP2024523006A (en) | 2024-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3222723B1 (en) | Development of universal cancer drugs and vaccines | |
US9783811B2 (en) | Inducible gene expression composition for using eukaryotic pol-2 promoter-driven transcription in prokaryotes and the applications thereof | |
US8779115B2 (en) | Short hairpin RNAs for inhibition of gene expression | |
ZA200601368B (en) | A self-processing RNA expression cassette | |
US7972816B2 (en) | Efficient process for producing dumbbell DNA | |
WO2014106011A1 (en) | Production and extraction of microrna precursor as drug for cancer therapy | |
Wu et al. | Mir-434-5p mediates skin whitening and lightening | |
US20220396798A1 (en) | Novel mrna composition and production method for use in anti-viral and anti-cancer vaccines | |
TWI720075B (en) | Use of microrna precursors as drugs for inducing cd34-positive adult stem cell expansion | |
TWI382849B (en) | Method of producing cosmetic product for skin care in ways of gene silencing effect and genetic recombinant nucleic acids encoding gene silencing effector | |
US9399773B2 (en) | Production and extraction of MicroRNA precursor as drug for cancer therapy | |
WO2022260719A1 (en) | Novel rna composition and production method for use in ips cell generation | |
US20170342418A1 (en) | Use of microrna precursors as drugs for inducing cd34-positive adult stem cell expansion | |
CN110295169B (en) | MiRNA and application thereof in killing Nilaparvata lugens | |
US20220396778A1 (en) | Novel RNA Composition and Production Method for Use in iPS Cell Generation | |
US20230295627A1 (en) | Novel Replicase Cycling Reaction (RCR) and the Related SamRNA Designs Thereof | |
US20220411848A1 (en) | Novel Replicase Cycling Reaction (RCR) | |
US20230099592A1 (en) | Novel replicase cycling reaction (rcr) | |
US20240093286A1 (en) | Novel Replicase Cycling Reaction (RCR) and the Related RdRP-Binding Site Designs Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22820710 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22820710 Country of ref document: EP Kind code of ref document: A1 |